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Elucidating a Common Mechanism of Proteasome Impairment in Neurodegenerative 
Disease and its Pharmacological Intervention 
Tiffany Ann Thibaudeau 
 
Proteostasis is maintained by several systems in the cell including the ubiquitin-proteasome 
system (UPS), chaperones, chaperone-mediated autophagy, and macroautophagy.  The UPS is 
the principle route for the degradation of intracellular misfolded, damaged, or unneeded cellular 
proteins and has a critical role essential every cell process, including: cell cycle progression, 
transcriptional regulation, genome integrity, apoptosis, immune responses, and neuronal 
plasticity. When the efficiency of protein degradation is perturbed, misfolded and damaged protein 
aggregates can accumulate to toxic levels and cause neuronal dysfunction, which may underlie 
many neurodegenerative diseases. It is widely appreciated that soluble oligomers of misfolded 
proteins (e.g. Aβ, Alzheimer’s; α-Syn, Parkinson’s; huntingtin with polyglutamine expansion, 
Huntington’s) and loss of proteostasis are the key drivers of disease development and 
progression. We show that three different proteins from Alzheimer’s, Parkinson’s, and 
Huntington’s disease that misfold and oligomerize into a shared three-dimensional structure 
potently impair the proteasome. Detailed mechanistic analysis demonstrates that these oligomers 
inhibit the 20S proteasome through allosteric impairment of the substrate-gate. To investigate the 
feasibility of proteasome gate-activation as a therapeutic strategy, we characterized the 
mechanism of proteasome gate activation by the conserved HbYX-motif found in proteasome 
activator complexes at the molecular level. Based on these observations, we developed a novel 
proteasome gate-activating molecule as a research tool to probe proteasome function in vitro and 
in vivo. Together, our results provide a novel molecular model for oligomer-driven proteasome 
impairment in neurodegenerative disease and demonstrate the feasibility of designing drug-like 
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Literature Review – Part 1  
 Neurodegenerative disease and the proteasome 
Neurodegenerative disease 
Patients with neurodegenerative disease commonly suffer from escalating dementia, memory 
loss, and motor impairment as their disease progresses, ultimately resulting in death. The most 
common, Alzheimer’s disease (AD), is the fourth leading cause of death in the elderly and a lead-
ing cause of poor health and disability1. Deaths due to AD increased by 68% over the past decade. 
The annual cost of care for AD is over $250 billion dollars,  and is projected to reach $1.2 trillion 
by 20501. The devastation caused by the development of AD on the individual and the family unit 
is remarkable. Moreover, if left untreated the expected catastrophic impact of AD on our aging 
nation has been extensively modeled and discussed 2. These facts clearly highlight the need for 
development of therapeutic strategies to combat these costly and deadly diseases. 
Compelling evidence from 
decades of research indi-
cates that diverse neuro-
degenerative diseases might 
have a common cause and 
pathological mechanism - 
protein misfolding, oligomer-
ization, and accumulation, 
resulting in loss of proteosta-




Figure 1. Characteristic neurodegenerative disease neuropathological lesions. 
(a) AD, neuritic plaque, silver stained (Hirano method)(cerebral cortex). (b) Alz-
heimer’s disease (AD), neuritic  plaque labeled for Aβ (cerebral cortex). (c) Parkin-
son’s disease (PD), Lewy bodies labeled for α-synuclein (substantial nigra). (d) Hun-
tington’s disease (HD), intranuclear inclusion labeled for huntingtin (cerebral cortex). 
Scale bar 50 µm. Figure adapted from [11]. 
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hypothesis postulated the extracellu-
lar, insoluble amyloid-fibrils were re-
sponsible for neuron death6. Early 
treatments focused on ameliorating 
pathologies visible with light micros-
copy (e.g. insoluble protein aggre-
gates: amyloid plaques, intracellular 
tangles, inclusion bodies) (Figure 1). 
However, visible pathology alone 
does not correlate well with disease7–
10 and clinical trials aimed at prevent-
ing the formation of or removing ex-
isting insoluble protein aggregates 
have failed11 (Figure 2).  The most 
likely explanation is the insoluble ag-
gregates represent an end-stage of 
the protein aggregation cascade, and that earlier intermediate steps in the cascade are directly 
tied to disease pathogenesis. In this proposed model, the insoluble protein aggregates may be 
protective by sequestering the toxic intermediates (Figure 2)12. Culminating evidence from the 
past two decades has revealed that soluble, oligomeric forms of protein aggregates (such as Aβ 
in Alzheimer’s disease, α-Synuclein in Parkinson’s disease, and mutant huntingtin in Huntington’s 
disease) are key players in proteostasis dysfunction13,14. It is now widely appreciated that soluble 
oligomers of misfolded proteins (e.g. Aβ, Alzheimer’s; α-Syn, Parkinson’s; huntingtin with poly-
glutamine expansion, Huntington’s) and loss of proteostasis are the key drivers of disease devel-




Figure 2. Flowchart for pathway of protein aggregation. After initiation 
event in protein aggregation, misfolded monomers adopt abnormal confor-
mations and begin to aggregate (1). Oligomeric (globular) intermediates then 
form, and protofibrillar structures are assembled (2). Amyloid fibers then 
form, resulting in aggregates or inclusions visible in the light microscope (3). 
Oligomeric (globular) intermediates are more toxic than the precursor protein 
or fibrillar aggregates and inclusions, which may be protective by sequester-
ing the toxic i9ntermediate forms. Figure adapted from [11]. 
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Proteostasis and the proteasome 
Proteostasis 20,21 is maintained by several systems in the cell including the ubiquitin-proteasome 
system (UPS), chaperones, chaperone-mediated autophagy, and macroautophagy22 (Figure 3), 
collectively called the Proteostasis Network (PN). If the efficiency of PN declines, misfolded pro-
teins begin to accumulate and aggregate in the cell, which can disrupt normal cellular functions 
and even cause cell death23. Maintaining proteostasis is especially important for neurons due to 
their complex architecture, long lifespan, and inability to dilute aggregate load by cell division24.  
Figure 3. The Proteostasis Network (PN). 
Balanced PN: Components of the PN (chaperones (blue spheres), the UPS, and autophagy) work together to maintain proteins in 
their native conformations and eliminate misfolded or metastable intermediates (blue arrows). On-pathway protein folding is high-
lighted with a blue background (left). The chaperone network (blue spheres) ensures correct folding and trafficking of nascent 
proteins. The proteasome degrades over 90% of the proteome, including intrinsically disordered proteins (IDPs) and folded proteins, 
and is the principal route for degradation of unneeded, damaged, misfolded or metastable proteins. Cellular stresses (including 
mutations, post-translational modifications, and oxidative damage) can partially unfold structured proteins (burgundy arrows). Par-
tially unfolded proteins (and IDPs) can be degraded by the 20S and 26S proteasomes, or self-associate to form aggregates (bur-
gundy arrows). In response to accumulation of misfolded proteins and aggregates, the chaperone network facilitates disaggregation 
and refolding of these proteins or directs them to the proteasome for degradation. Large bulk aggregates resistant to disaggregation 
are removed by macroautophagy. PN Collapse: When the efficiency of the PN declines, misfolded and metastable proteins accu-
mulate. Protein aggregates cause cellular toxicity, in part through aberrant interactions with cellular proteins, sequestering chaper-
ones, and by impairing the UPS. PN, proteostasis network ; UPS, ubiquitin proteasome system; IDP, intrinsically disordered protein;   




The UPS is the principle route for the degradation of intracellular misfolded, damaged, or un-
needed proteins25. The UPS is critical for normal functioning of neuronal synapses, including syn-
aptic protein turnover, plasticity, and long-term memory formation, all of which rely on tightly con-
trolled changes in the proteome24,26–28. Recently, Ramachandran and Margolis29 identified a spe-
cialized neuronal membrane proteasome (NMP) that mediates neuronal function by “inside-out” 
signaling through the production of extracellular proteasome-derived peptides. Pharmacological 
dissection of the downstream pathways of peptide signaling revealed that NMP-derived peptides 
act in part by modulating postsynaptic N-methyl-D-aspartate receptors (NMDARs), and it is well-
well-known that NMDARs are critical for neuronal activity-dependent signaling relevant to learning 
and memory30,31. 
It is well established that pro-
teasome function is decreased in 
neurodegenerative diseases, and 
impaired function has been impli-
cated in the development of many 
neurodegenerative diseases, in-
cluding Alzheimer’s, Parkinson’s, 
and Huntington’s diseases4,32–35. 
Experimental proteasome inhibition 
in animals recapitulates many as-
pects of human neurodegenerative diseases36–39. For example, stereotaxic unilateral infusion of 
lactacystin (a selective proteasome inhibitor) into the substantia nigra pars compacta of rats 
caused neurodegenerative disease like symptoms40. Several groups have provided evidence that 
aggregated proteins from neurodegenerative diseases interact with and impair proteasome41–49 
(Figure 4). We recently identified a mechanism by which neurodegenerative-disease related 
Figure 4. Protein misfolding and proteasome impairment. Neurodegen-
erative diseases (ND) share the accumulation of toxic protein oligomers 
(soluble aggregates). Ubiquitin proteasome system (UPS) impairment is 
also a common feature, which can alone lead to neuronal death and ND-
like symptoms. Specific toxic oligomer conformations impair proteasome 




protein oligomers (Aβ, -synuclein, and mutant huntingtin) impair the proteasome50. Our results 
provide a novel molecular model for oligomer-driven impairment of proteasome function that is 
relevant to a variety of neurodegenerative diseases.  
Increased proteasome activity shown to be beneficial in many related disease models. Drugs that 
reverse proteasome impairment in neurodegenerative disease are expected to restore cellular 
proteostasis, thereby reducing neuronal loss and simultaneously stimulate clearance of toxic oli-
gomers by depleting the pool of misfolded monomers. Such therapeutic interventions have the 
potential to restore proteostasis in patients suffering from neurodegenerative diseases, as evi-
denced by several recent studies. For example, Choi et al.51 showed that opening of the 20S 
proteasome gate (thereby increasing proteasome activity) in cells leads to enhanced cellular pro-
teasome function, including ubiquitin-dependent protein degradation, decreased protein aggre-
gation, and confers protection from oxidative stress. A better understanding of the proteasome 
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The Ubiquitin Proteasome System (UPS) degrades individual proteins in a highly regulated 
fashion and is responsible for the degradation of misfolded, damaged, or unneeded cellular 
proteins. During the past 20 years, investigators have established a critical role for the UPS in 
essentially every cellular process including: cell cycle progression, transcriptional regulation, 
genome integrity, apoptosis, immune responses, and neuronal plasticity. At the center of the UPS 
is the proteasome, a large and complex molecular machine containing a multicatalytic protease 
complex. When the efficiency of this proteostasis system is perturbed, misfolded and damaged 
protein aggregates can accumulate to toxic levels and cause neuronal dysfunction, which may 
underlie many neurodegenerative diseases. In addition, many cancers rely on robust proteasome 
activity for degrading tumor suppressors and cell cycle checkpoint inhibitors necessary for rapid 
cell division. Thus clinically, proteasome inhibitors have proven useful to treat some types of 
cancer, especially Multiple Myeloma. Numerous cellular processes rely on finely tuned 
proteasome function, making it a crucial target for future therapeutic intervention in many diseases 
including neurodegenerative diseases, cystic fibrosis, atherosclerosis, autoimmune diseases, 
diabetes, and cancer. In our review, we discuss the structure and function of the proteasome, the 
mechanisms of action of different proteasome inhibitors, various techniques to evaluate 
proteasome function in vitro and in vivo, proteasome inhibitors in preclinical and clinical 
development, and the feasibility for pharmacological activation of the proteasome to potentially 
treat neurodegenerative disease.   
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Prologue 
Early biologists viewed cellular proteins as essentially stable constituents subjected to only minor 
'wear and tear'. The widely accepted theory was that dietary proteins functioned primarily as 
energy, providing fuel for the body. Rudolf Schoenheimer and colleagues challenged that notion 
in the late 1930s using stable isotopes to show that trace dietary amino acids rapidly incorporated 
into tissue proteins 1 and that these proteins are in a dynamic state of synthesis and degradation 
2. Today we understand that all intracellular proteins are continually “turning over;” i.e., they are 
being hydrolyzed into their constituent amino acids and replaced via de novo synthesis. Individual 
proteins are degraded at different rates; varying from minutes for certain regulatory enzymes, to 
days for myosin heavy chain in cardiac muscle, to months for hemoglobin in erythrocytes 3. While 
cytosolic proteins can be degraded in lysosomes (via chaperone-mediated autophagy and 
macroautophagy), the majority are degraded by the proteasome 4. 
 The discovery of a special class of cytoplasmic granules containing acid hydrolases in the 50’s 
5,6, called lysosomes 7, was an important step forward in understanding intracellular protein 
breakdown. Breakdown of endogenous (autophagy) and exogenous (heterophagy) material was 
believed to occur in lysosomes, the 'intracellular digestive system' 8. Because, peptide hydrolysis 
is an exergonic (i.e. downhill)  reaction, the discovery of ATP-dependent protein breakdown in 
mammalian 9 and bacterial cells 10 was unexpected. Simpson et al. suggested "the possible 
existence of two (or more) mechanisms of protein breakdown, one hydrolytic, the other energy-
requiring" 9. Subsequent work over the next two decades firmly established that both rates of 
protein synthesis and degradation determine the cellular protein concentration as well as the wide 
variability of protein half-lives 11–13.  
Studies in the 1970’s supported the prediction of a new selective degradation pathway that 
accounted for the wide distribution of protein half-lives 14–17. Interestingly, cytosolic proteins 
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synthesized with structural analogues of a normal amino acids are rapidly degraded within the 
cell 14,18,19. These seminal observations added another layer of selectivity in which the inherent 
stability of each protein also determines the degradation rate, presumably to prevent the 
accumulation of abnormal proteins 19. However, the mechanism of selectivity remained a mystery. 
ATP was found to be essential for protein catabolism but it was unknown whether a proteolytic 
step was directly dependent on ATP or whether it required some additional reactions 20. Selective 
and ATP-dependent protein degradation was not congruent with the notion of the lysosome as 
the key player in protein breakdown. What could be responsible for this exquisitely controlled 
protein degradation? In 1977 Etlinger and Goldberg identified a novel, soluble, ATP-dependent 
proteolytic system that was independent from the lysosome 21. The importance of the soluble 
degradation system was emphasized when Rechsteiner and colleagues showed that most 
intracellular proteins are degraded in the cytosol, not the lysosome 22. 
Wilk and Orlowski (1980) purified a 700 kilodalton (kDa) 'multicatalytic proteinase complex' (later 
shown to be the 20S proteasome) 23. Unlike all other known proteases, this new protease complex 
could cleave peptides after basic, acidic, or hydrophobic residues, suggesting that it contained 
multiple distinct active sites 23,24. Electron micrographs revealed the complex to be a 700 kDa 
stacked ‘donut’ ring structure 25. Due to their critical roles in intracellular protein breakdown, these 
protease complexes were collectively renamed 'proteasomes' 26. Analogous protease complexes 
of equivalent size, shape, polypeptide composition, and proteolytic activities have since been 
identified across all three domains of life 25,27. 
The next major advancement in the field came with the discovery of ubiquitin (Ub), a small ~8 
kDa protein with a big role in protein degradation. Aaron Ciechanover and colleagues identified a 
small heat-stable protein, ubiquitin, covalently conjugated to target substrates 28, in an ATP-
dependent manner 29,30. This led to the proposed model in which protein-substrate modification 
by several ubiquitin moieties targets it for degradation by a downstream, as-yet unidentified 
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protease that cannot recognize the unmodified substrate 31. It was later shown that some non-
ubiquitin proteins are also degraded in an ATP-dependent manner 32. Rechsteiner's group later 
went on to purify the ATP-dependent 26S proteasome responsible for ubiquitin conjugate 
degradation 33,34. 
Avram Hershko, Aaron Ciechanover, and Irwin Rose characterized the system of Ub conjugation 
and its role in marking proteins for degradation 35 – an achievement that earned them the Nobel 
Prize in Chemistry (2004) 36. Attachment of poly-Ub chains to specific proteins selects them for 
proteasome-mediated degradation (Figure 1A). Targeting proteins for degradation requires three 
enzymatic components to link chains of Ub onto selected protein substrates. E1 (Ub-activating 
enzyme) and E2s (Ub-carrier or conjugating proteins) prepare Ub for conjugation. The E3 (Ub-
protein ligase) enzymes control substrate specificity, recognizing substrate degradation signals 
and catalyzing the transfer of activated Ub to the substrate 35,37. Eukaryotic cells contain hundreds 
of E3 ligases allowing the cell to precisely control ubiquitination and degradation of individual 
proteins 38. Ubiquitin conjugation is necessary for cell viability 39,40 and activity of the ubiquitin 
pathway is greatly increased in cells making abnormal proteins 41. 
During the past 20 years, investigators have established the critical role of the UPS in cell cycle 
progression 42–44, transcriptional regulation, genome integrity, apoptosis, immune responses 45, 
and the pathogenesis of many human diseases 4,46. With respect to disease, the proteasome is 
particularly important for maintaining cellular protein homeostasis (i.e. proteostasis). When the 
efficiency of proteostasis systems decline, misfolded and damaged proteins aggregate to toxic 
levels within the cell, potentially giving rise to many neurodegenerative diseases 47,48. Too much 
of a good thing can be just as detrimental. Cancer cells rely on robust proteasome activity for 
degrading tumor suppressors and cell cycle checkpoint inhibitors necessary for rapid cell division 
49. Numerous processes rely on finely tuned proteasome function, making it a crucial target for 
therapeutic intervention in many diseases including neurodegenerative diseases, cystic fibrosis, 
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atherosclerosis, autoimmune diseases, diabetes, and cancer 50. In 2003 bortezomib (Velcade®) 
became the first US Food and Drug Administration (FDA) approved proteasome inhibitor as a 
third line treatment for multiple myeloma (MM).   
In this review, we first discuss the structure, function, and regulation of the proteasome. Then we 
discuss the classes and mechanisms of action of Proteasome Inhibitors (PIs). Next, we 
summarize commonly used in vitro and in vivo techniques for studying proteasome activity and 
inhibition followed by a review of currently FDA approved proteasome inhibitors (PIs) as well as 
novel inhibitors undergoing clinical and preclinical trials. Lastly, we discuss how pharmacological 
activation of the proteasome- could produce novel therapeutics to treat neurodegenerative 
disease.    
I. Proteasome structure and function. Overview of the current understanding of 20S/26S 
proteasome structure, mechanism of protein degradation, and the cellular processes associated 
with proteasome impairment or hyperactivation in human diseases.  
II.  Development of proteasome inhibitors. Proteasome inhibitor classes and mechanisms of 
action, mechanisms of proteasome inhibitor resistance, and considerations for proteasome 
inhibitor design. 
III.  Methods for pharmacological proteasome research. Overview of in vitro and in vivo 
methods for investigating proteasome activity  
IV.  Proteasome inhibitors to treat human disease. Review FDA approved proteasome 
inhibitors, clinical trials, and pre-clinical research to treat cancer and inflammatory disease, 
including strategies aimed at overcoming proteasome inhibitor resistance. 
V.  Novel proteasome pharmacological targets. Novel proteasome targets for modulating 
proteasome activity. 
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I. Proteasome Structure and Function 
I.A. Proteasome structure and activity 
The 26S proteasome is a 2.4 megadalton (MDa) molecular machine that  makes up nearly 2% of 
total cellular protein 51. It is composed of a 20S proteasome core particle capped on one or both 
ends by the 19S regulatory particle (Figure 1B). It degrades proteins by a multistep process; the 
19S regulatory particle binds ubiquitinated substrates, opens a substrate entry gate in the 20S 
52,53, and unfolds its substrates by linearly translocating them into the 20S catalytic chamber where 
they are degraded to peptides 54,55. Numerous studies over the past two decades have developed 
our present understanding of proteasome structure and function. The first 20S core particle was 
crystalized in the late 90's 56. Since then hundreds of 20S structures, complexed with regulators 
or inhibitors, have been solved.  
Eukaryotic proteasomes contain four stacked heteroheptameric rings arranged in an α7-β7-β7-α7 
fashion 56. The amino(N)-termini of the α subunits form a "gate,” folding over the 13 Angstrom 
central pore and occluding access to the proteolytic sites located on the β subunit lumen 57. 
Passage through this gate is the rate limiting step and prevents unregulated protein degradation 
58. The α N-termini tails are highly conserved, containing a tyrosine-aspartate-arginine (YDR) motif 
that forms salt bridges with neighboring tails that obstruct the 13A entry pore. The α3 N-terminus 
is the lynchpin, critical for stabilizing the closed gate confirmation 58. Note that the purified latent 
20S proteasome still exhibits a degree of peptidase activity due to stochastic conformational 
fluctuations within the N-termini 59,60. Interestingly, deletion of the first eight α3 residues (α3∆N-
20S) sufficiently destabilizes the closed-gate conformation and accelerates the entry and 
degradation of peptides 58. α3∆N-20S crystallographic structures show that the remaining N-
termini are disordered resulting in a constitutively open gate 58.  Wild type 20S proteasome activity 
is similarly accelerated when bound to a proteasome activator (e.g. 19S/PA700, 11S/PA28, 
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Blm10/PA200) 61. Proteasome activators bind to a free end of the α subunit ring and "open" the 
gate by distinct mechanisms that are discussed in detail below.  
I.A.1. Active sites of the 20S. The eukaryotic 20S proteasome contains six proteolytically active 
β-subunits, three on each β-ring that exhibit different substrate preferences (Figure 2A and 2B). 
The various substrate binding pockets determine active site specificity like classical proteases but 
with more complexities. The binding pockets themselves are formed by specific interactions 
between the catalytic subunit and the neighboring β-subunit 62. As a result, the proteasome is not 
simply a complex of independent proteases but is a unique multicatalytic enzyme functioning only 
when wholly intact. The chymotrypsin-like site (β5) preferentially cleaves after hydrophobic 
residues, the trypsin-like site (β2) preferentially cleaves after basic residues, and the caspase-like 
site (β1) preferentially cleaves after acidic residues 55,63. Despite their names, these sites do not 
share the catalytic mechanisms of their namesakes and their substrate preferences are much 
broader than the names imply 51. Multiple catalytic sites with varying specificities advantageously 
allow for the rapid and processive degradation of cellular proteins.  
All proteasome active sites utilize an N-terminal threonine nucleophile. Enzyme inhibitor and site-
directed mutagenesis studies compose much of what we know about the proteasome’s unusual 
catalytic mechanism 64. Although lacking the classical triad of cysteine and serine proteases, 
proteasome sensitivity to peptide aldehyde inhibitors suggests a similar catalytic mechanism 64. 
Accordingly, the crystal structure of the 20S bound to the peptide aldehyde Ac-Leu-Leu-nLeu-al 
(ALLN)  reveals a hemiacetyl bond between the β subunit N-terminal threonine hydroxyl groups 
64. Proteasome inhibitors (lactacystin, vinyl sulfones, and epoxyketones) are often found to 
covalently modify this threonine. As expected, mutation to a serine residue retains significant 
activity while mutation to an alanine residue completely abolishes activity 64.  
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1.A.2. Specialized catalytic subunits. Some cell types express  subunits with modified catalytic 
sites under certain conditions. Immune cells constitutively express  alternative catalytic subunits 
(β1i/LMP2, β2i/MECL-1, and β5i/LMP7) that are preferentially incorporated into the 20S 
proteasome de novo in place of the constitutive β1 (β1c), β2 (β2c), and β5 (β5c) subunits, forming 
the immunoproteasome 65 (Figure 2A). The immunoproteasome is also expressed in 
nonhematopoietic cells when exposed to interferon (INF)-γ or tumor necrosis factor (TNF)-α 65. 
To our best knowledge the main purpose of the immunoproteasome is to enhance ligand 
generation for major histocompatibility complex class I (MHC-I) molecules  66 that allow for 
immune surveillance 67. How do these immune subunits do this? These subunits use the same 
catalytic mechanism as their constitutively expressed counterparts but they have different 
cleavage preferences due to changes in substrate binding pockets 64,68. The most striking 
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difference between constitutive and immunoproteasomes is the β1i subunit, which lacks caspase-
like activity but instead cleaves after hydrophobic residues 64. This is a crucial difference because 
only MHC-I molecules with tightly bound ligands are expressed on the cell surface. Tight class-I 
binding requires ligands 8-9 amino acids in length with either a hydrophobic or basic anchor 
residue at the carboxy(C)-terminus. Ligands with acidic C-termini are not accepted 69,70. Thus, the 
immunoproteasome facilitates the production of peptides suitable for MHC-I presentation 66.  
Human thymus cortical epithelial cells express a thymic-specific catalytic subunit β5t, which 
together with β1i and β2i form the thymoproteasome 71 (Figure 1A). The thymoproteasome is 
essential for T lymphocytes positive selection. Compared to β5c and β5i, the β5t has weak 
chymotrypsin-like activity, thus it is speculated that thymoproteasomes facilitate the low affinity 
MHC-I molecule ligand production necessary for positive selection 71. Further details on unique 
functions of tissue-specific proteasomes can be found in Kniepert & Groettrup (2014) 70.  
1.A.3. Proteasome regulatory caps and their diverse biological roles. Regulation of gate 
opening in the 20S proteasome is an important aspect of proteasome function, and as such the 
cell has evolved many different proteasomal regulators that control 20S gate-opening 61. The most 
well-known regulator is the 19S (also known as PA700), a component of the 26S proteasome. 
The 26S proteasome is a structurally dynamic complex, adopting large-scale conformational 
changes around the central axis during the ATP-dependent processing of substrates 72–75. These 
structural changes appear to be necessary for substrate protein unfolding and injection into the 
20S core particle.  
Ubiquitin-dependent degradation requires several steps: (1) substrate binding and commitment, 
(2) 20S gate opening, (3) substrate unfolding and translocation, and (4) deubiquitination (Figure 
2B). (1) The 19S regulatory particle has three integral subunits that serve as substrate receptors: 
Rpn1, Rpn10, and Rpn13. These substrate receptors reversibly associate with Ub, and have only 
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low affinity for mono-Ub 76. The multiplicity of Ub receptors coupled with a variety of shuttling 
factors (e.g. proteins that have a ubiquitin-like domain (UBL) and a ubiquitin associating domain 
(UBA)) allows the 26S proteasome to recognize and degrade many types of Ub conjugates 77. 
Substrate binding to the Ub receptors induces a conformational change aligning the 19S ATPase 
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translocation channel directly over the 20S gate 73, induces gate opening, and stimulates ATP 
hydrolysis 78,79. Substrate commitment requires a loosely folded region of the protein (e.g. 
unstructured initiation site) to insert into the ATPase ring where tyrosine pore loops inside the 
ATPase ring “grip” the substrate in an ATP-dependent manner 80. (2) The six ATPase subunits 
(Rpt1-6) form a ring at the bottom of the 19S complex with their C-termini inserting into the 20S α 
subunit intersubunit pockets 82. 19S-dependent gate-opening requires ATPase C-terminal HbYX 
motif binding to intersubunit pockets (between the α subunits) on top of the 20S 83. Binding  of the 
19S C-termini to the 20S is thought to induce a conformational change in the α subunits, opening 
the gate 82. The exact mechanisms behind the 26S HbYX-motif gate opening in human 26S 
proteasomes are not clear. However, binding of a HbYX-motif peptide (the last 8 residues of Rpt5) 
is sufficient to allosterically induce conformational changes in the 20S -subunit and open the 
gate 84. (3) The six ATPase subunits power processive unfolding and translocation of substrates 
into the 20S core coupled with ATP hydrolysis 85,86. (4) Rpn11 is the integral proteasomes-
associated deubiquitinase (DUB) enzyme of the 19S complex. Rpn11 is positioned directly above 
the translocation channel when substrate is committed for degradation and removes the entire 
Ub chain as proteins are translocated 76. Two other DUBs are transiently associated with 
proteasomes (Usp14 and Uch37) and they can trim substrate Ub chains prior to the committed 
step, rescuing the substrate from degradation 76.  Proteasome associated DUBs are discussed in 
Part V.  
In addition to the 19S, there are two other proteasome gate activator families, the 11S and 
PA200/Blm10, neither of which contain unfoldase activity or require ATP (Figure 2C). Higher 
eukaryotes express three 11S regulatory subunits, PA28α,β,γ (aka REGα,β,γ) 87,88.  PA28αβ 
forms inducible heteroheptamer that is primarily located in the cytoplasm. In contrast, PA28γ 
forms a homoheptamer that is constitutively expressed in the nucleus 61,89. The biological roles of 
these regulators remain relatively mysterious. However, both forms of PA28 regulators show 
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increased expression following acute oxidative stress in cells, suggesting both play a significant 
role in oxidized protein degradation 90. Additionally, IFN-γ increases PA28αβ expression, oxidized 
protein degradation capacity 90, and MHC-I ligand generation.  
PA200 (Blm10 in yeast) plays a role in spermatogenesis 91, response to DNA repair 92, glutamine 
homeostasis 93, and mitochondrial inheritance 94, although molecular details behind many of these 
functions are not clear. The crystal structure of yeast Blm10-20S shows that Blm10 forms a large 
HEAT repeat-like solenoid in a 1.5 super helical turn, forming a dome that caps the ends of the 
20S proteasome 94. One C-terminal HbYX motif binds between the α5 and α6 intersubunit pocket 
and facilitates gate opening 95,96. As with the 19S Rpt5 subunit, an eight-amino acid Blm10 C-
terminal fragment (Blm-pep) induces gate opening in purified 20S proteasomes 97. The Blm-pep 
bound 20S crystal structure closely resembles the bound HbYX in the full-length Blm10 structure.  
PA200/Blm10 containing proteasomes specifically catalyze the acetylation-dependent, but not 
polyubiquitination-dependent, core histone degradation during somatic DNA damage response 
and spermatogenesis 98. During spermatogenesis, the spermatoproteasome (formed by PA200, 
20S, β1i, β2i, β5i and the human testis specific α4s) degrades core histones and is required for 
proper sperm maturation and viability 98. The existence of such proteasomes highlights the 
seemingly infinite complexities of the cell’s repertoire of proteasome complexes for specific 
cellular roles. 
I.B. Proteasome dependent cellular processes 
Proteasome function is essential to cellular homeostasis. In addition to maintaining proteostasis, 
the proteasome plays a key role in the regulating many physiological processes. Four major areas 
not previously discussed include cell cycle regulation, NF-κB activation, neuronal function, and 
ER-associated protein degradation (Figure 3). 
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I.B.1. Cell Cycle. The proteasome degrades many cell cycle regulatory proteins that typically 
have short half-lives (e.g. cyclin B1, p21, p27) and tumor suppressors (e.g. p53) promoting cycle 
progression 99–103. Not surprisingly, most cancers heavily rely on proteasome activity and are more 
susceptible to proteasome inhibition than normal cells 104–106. Proteasome inhibition in cancer is 
discussed in Part III.  
I.B.2. NF-κB Activation. The NF-κB transcription factors (NF-κB and Rel proteins) regulate 
expression of genes involved in innate and adaptive immunity, inflammation, stress responses, B 
cell development, and lymphoid organogenesis. In cancer cells, NF-κB is critically involved in the 
expression of the antiapoptotic IAP family of genes as well as BCL-2 pro-survival genes 107–109. 
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Canonical and a non-canonical NF-κB activation requires proteasome-mediated degradation of 
regulatory elements for transcriptional activation. In the unstimulated state, the inhibitory IκB 
subunits bind and sequester NF-κB/Rel complexes in the cytoplasm 110. In canonical pathway 
activation, proinflammmatory cytokines activate the IKK complex (IKKβ, IKKα, and NEMO) which 
phosphorylates IκB, leading to IκB ubiquitination and proteasomal degradation 111–114,  freeing NF-
κB/RelA complexes. Freed NF-κB/RelA complexes translocate to the nucleus where they (either 
alone in or combination with other transcription factors) induce target gene expression. In the 
noncanonical pathway, NF-κB-p100/RelB complexes are inactive in the cytoplasm. Signaling 
activates the kinase NIK, which activates IKKα complexes that phosphorylate NF-κB2-p100 C-
terminal residues. Phosphorylated NFκB is ubiquitinated and processed by the proteasome into 
NF-κB2-p52, which is transcriptionally competent. Such processing by the proteasome is 
remarkable since it requires the initiation of protein degradation, followed by termination of 
degradation at a specific domain, demonstrating exquisite control over degradation. After 
processing, NF-κB2-p52 translocates to the nucleus and induces target gene expression. NF-κB 
is a pro-survival pathway and is upregulated in many cancers and inflammatory diseases 115. 
Given the indispensable role of proteasome function in activating this pathway, proteasome 
inhibition is a valid therapeutic target. The role of NF-κB in cancer pathology is discussed further 
in Part IV.  
I.B.3. Neuronal function. Maintaining proteostasis in neurons is especially important due to their 
complex architecture, long lifespan, and inability to dilute aggregate load through cell division 116. 
Importantly, the UPS is critical for normal functioning of neuronal synapses, including synaptic 
protein turnover, plasticity, and long-term memory formation, which rely on tightly controlled 
changes in the proteome 116–119. In addition to the intracellular proteasomes, Ramachandran and 
Margolis (2017) identified a mammalian nervous-system-specific membrane-associated 
proteasome complex that rapidly modulates neuronal function 120. This proteasome complex 
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degrades intracellular proteins and releases the products into the synaptic cleft where they 
stimulate postsynaptic N-methyl-D-aspartate receptor-dependent neuronal signaling, a process 
important for regulating synaptic function.  
The accumulation of aggregation-prone proteins is a hallmark of neurodegenerative disease 
commonly accompanied by loss of proteostasis and progressive death of neurons 121–123. It is 
established that proteasome function is decreased in neurodegenerative diseases, and its 
impairment is implicated in the development of many neurodegenerative diseases including 
Alzheimer’s, Parkinson’s, and Huntington’s diseases 122,124–127. To highlight this point, brain 
region-specific proteasome inhibition closely mirrors the neuropathology and clinical hallmarks of 
neurodegenerative diseases 128–131. The importance of targeting the proteasome for potential 
neurodegenerative disease therapy is discussed in Part V.         
I.B.4. Endoplasmic reticulum-associated protein degradation and the unfolded protein 
response. Secretory proteins and most integral membrane proteins are synthesized and enter 
the endoplasmic reticulum (ER) lumen for proper folding and covalent modifications. The ER-
associated protein degradation (ERAD) pathway is an evolutionarily conserved process that 
discards misfolded ER proteins 132. Three different ERAD pathways (ERAD-L, -M, and -C) are 
utilized for degrading misfolded ER proteins, depending on whether their misfolded domain is 
localized in the ER lumen, within the membrane, or on the cytosolic side of the ER membrane, 
respectively 133–135. A fourth pathway is responsible for misfolded protein removal from the inner 
nuclear membrane 136,137. Each pathway involves distinct Ub ligases and co-factors, although it is 
unclear how proteins are targets to each pathway. ERAD substrates from all pathways are 
retrotranslocated to the cytosolic side of the membrane 132. With the help of ubiquitination 
machinery and the Cdc48/p97 ATPase complex, the substrates are extracted from the membrane 
and delivered to the 26S proteasome for degradation 138–141. Proteasome inhibition stalls ERAD 
and causes misfolded proteins to accumulate within the ER. In response, the cell activates a 
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highly conserved signaling pathway called the unfolded protein response (UPR) 142. Multiple 
physiological conditions also lead to accumulation of misfolded proteins in the ER and subsequent 
UPR activation, including hypoxia, glucose deprivation, oxidative stress, and mutations in certain 
secretory proteins 142. UPR activation regulates the gene expression involved in protein folding 
(e.g. chaperones) and ERAD, and decreases protein translation into the ER in an attempt to 
restore ER homeostasis 143. The UPR initially performs a protective role in the cell. However, 
prolonged ER stress and UPR activation eventually leads to cell death 143. Wu and Rapoport 
(2018) recently published an extensive review discussing the molecular mechanisms of ERAD 
and associated protein degradation 132.  
II. Development of Proteasome Inhibitors (PIs) 
II.A. The Rise of Proteasome Inhibitors  
Our understanding of the importance of the UPS for biological functions and processes rapidly 
advanced with the introduction of the first proteasome inhibitors 144. These valuable tools allowed 
researchers to interrogate proteasome function in complex cellular systems and tissues, and 
greatly advanced our understanding of many aspects of cell regulation, disease mechanisms, and 
immune surveillance 66. Perhaps the most clinically important developments to come from the 
early proteasome inhibitor studies were advancements in understanding the regulation of NF-κB 
and its key role in the pathogenesis of many inflammatory and neoplastic diseases 27,145. The first 
proteasome inhibitors were simple hydrophobic peptide aldehydes (analogues of serine protease 
inhibitors) designed to mimic the preferred substrates of the proteasome's chymotrypsin-like site 
(β5) and inhibit it 27. The tri-peptide aldehyde, MG132 (carbobenzyl-Leu-Leu-Leu-aldehyde), is 
still the most widely used proteasome inhibitor in scientific research because it is potent, 
inexpensive, and quickly reversible 27. Given the indispensable role of the proteasome in this 
pathway, proteasome inhibitors showed therapeutic potential for the treatment of some human 
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diseases, yet it was also appreciated that complete proteasome inhibition would lead to cell death 
27.  
Researchers hypothesized that partial and reversible inhibition of the proteasome might be 
beneficial in killing neoplastic cells because they lack many of the checkpoint mechanisms that 
protect normal cells from apoptosis 27,146. Accordingly, proteasome inhibitors were preferentially 
toxic to transformed and patient derived malignant cell cultures rather than their non-transformed 
and healthy counterparts 146,147. Aldehyde proteasome inhibitors (e.g. MG-132) had limited 
therapeutic potential in humans due to off-target effects (e.g. inhibition of cathepsin B and 
calpains) and poor metabolic stability 148. With MG-132 as a lead compound, a team of medicinal 
chemists led by Julian Adams synthesized PS-341 (a dipeptide boronic acid), a slowly reversible 
inhibitor of the β5 active site (with some activity toward the β2 active site). PS-341 proved to be 
a potent and selective proteasome inhibitor demonstrating therapeutic activity in preclinical 
models of inflammatory diseases and human cancers 146,147,149. PS-341 entered phase I clinical 
trials where remarkably one patient with multiple myeloma (MM) showed a complete response to 
PS-341 treatment 146. MM is an incurable plasma cell malignancy and at that time patients had a 
poor prognosis due to lack of effective treatment options, making the complete response to PS-
341 a dramatic clinical breakthrough 27. PS-341 progressed to phase II trials for MM and chronic 
lymphoid leukemia. Due to the remarkable success of PS-341 in phase II trials, the FDA approved 
PS-341 (later renamed bortezomib and marketed it as Velcade®) (Figure 4A) as a third-line 
treatment for relapsed and refractory multiple myeloma (RRMM) in 2003 27. Bortezomib 
revolutionized the treatment of MM and today bortezomib is approved for use as a first line therapy 
for MM and mantle cell lymphoma.  
Despite the clinical success in treating hematological diseases, bortezomib therapy is associated 
with a high rate of resistance (primary or secondary) and serious dose-limiting toxicity which 
require reduction or discontinuation of the drug 150. Advances in proteasome inhibitor chemistry 
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and a better understanding of the proteasomes unique catalytic mechanism have led to the 
development of second generation proteasome inhibitors with improved pharmacokinetics when 
compared to bortezomib 151. The mechanisms of available PIs and their uses in research and 
clinical settings are discussed in the following sections.   
II.B. Chemical Classes of Proteasome Inhibitors 
There are several classes of proteasome inhibitors. Like the majority of protease inhibitors, most 
proteasome inhibitors are short peptides designed to fit into the substrate binding site on the 
catalytic subunit. The activity of proteasome inhibitors depends on the pharmacophore warhead 
at the C-terminus, which reacts with the active site threonine nucleophile to form a reversible or 
irreversible covalent adducts 51. Although the proteasome has three types of catalytic sites, 
inhibition of all three is not required to significantly affect protein degradation 152. Specific β1 or 
β2 inhibition does not have a significant effect on overall protein breakdown, however, β5 
inhibition results in significantly reduced protein breakdown 152. Consequently, most proteasome 
inhibitors target the β5 site, although they often have some lesser activity against β1 and/or β2 
152.  
II.B.1. Peptide Aldehydes. Based on the well-characterized serine and cysteine protease 
inhibitors, peptide aldehydes (e.g. MG132) were the first synthesized proteasome inhibitors. 
MG132 is cell-permeable and a reversible proteasome inhibitor, which makes it a valuable 
research tool. Because MG132 has slow binding and fast dissociation kinetics (Kisselev and 
Goldberg, 2001), the effects of MG132 proteasome inhibition on cultured cells is quickly reversed 
by switching to inhibitor-free media. The low cost and rapid reversibility make MG-132 the most 
used proteasome inhibitor for research 27. However, there are several limitations to MG-132. First, 
MG-132 in cell culture media is rapidly oxidized into an inactive acid 51. For long cell culture 
experiments, MG-132 containing media should be replaced daily. Second, as other peptide 
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aldehydes, MG-132 also inhibits (albeit with much lower affinity) calpains and cathepsins 51, 
therefore it is necessary to perform control experiments to confirm that the observed effects are 
due to proteasome inhibition.  Proteasome involvement can be verified using a more selective 
proteasome inhibitor (e.g. epoxomicin, boronates, and lactacystin), although these compounds 
may be cost prohibitive for routine studies/screens. Additionally, inhibitors that specifically block 
other proteases (e.g. E-64 for calpains), but not the proteasome, can be used to confirm the 
observed effect is not due to off target inhibition of another protease. 
II.B.2. Peptide Boronates. Peptide boronates are significantly more potent proteasome inhibitors 
when compared to peptide aldehydes. Like peptide aldehydes, peptide boronates form a 
tetrahedral adduct with the active site threonine, but their dissociation rate is much slower making 
boronates practically irreversible over hour scale time courses 51. MG-232, the boronate version 
of MG-132, is 100-fold more potent than its aldehyde counterpart 51. Additionally, peptide 
boronates are not oxidized into inactive forms like MG-132, making them more stable in vivo 51. 
The boronate pharmacophore cannot react with active site cysteines, so they have fewer non-
proteasome targets 51.  
II.B.3. Epoxomicin & Epoxyketones. Another naturally derived proteasome inhibitor is 
epoxomicin, an actinomycete fermentation metabolite. It is a modified peptide that contains a C 
terminal ',' -epoxyketone group attached to an aliphatic P1 amino acid 51. Epoxomicin is 
extremely specific for the proteasome. The crystal structure of yeast 20S proteasome in complex 
with epoxomicin revealed its unusual mechanism of action and explained the basis for 
proteasome specificity 57. Epoxomicin reacts covalently with both the catalytically active N-
terminal threonine hydroxyl and the free amino group, producing a highly stable and irreversible 
morpholino ring 57. Unlike other PIs that only form a bond with the threonine hydroxyl, the double 
covalent bond formation of the epoxyketone group limits its reactivity to the N-terminal nucleophile 
threonine proteases without inhibiting any other cellular protease 64. Since the discovery of 
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epoxomicin as a proteasome inhibitor many ',' epoxyketone electrophiles have been 
incorporated into peptides sequences and optimized for binding to the proteasome  subunits . 
The most well-characterized epoxyketone inhibitor is carfilzomib (Kryopolis®, Onxy Pharm / 
Takeda) (Figure 4A), a second-generation FDA approved proteasome inhibitor for treatment of 
RRMM and is discussed further in Part IV.   
II.B.4. Lactacystin and beta-lactone. Lactacystin, a Streptomyces metabolite, is a non-peptide 
proteasome inhibitor. Lactacystin itself does not inhibit the proteasome, but at neutral pH 
lactacystin spontaneously converts to clasto-lactacystin-β-lactone which is reactive with the 
proteasome. The β-lactone reacts with the proteasome active site threonine resulting in opening 
of the β-lactone ring and acylation of the proteasome catalytic threonine hydroxyl 64. The yeast 
20S proteasome in complex with lactacystin crystal structure confirmed this mechanism providing 
strong evidence that an acyl enzyme conjugate is an intermediate in proteasome catalysis 64. 
Lactacystin is more proteasome-specific than MG132, with a single off target substrate, cathepsin 
A. Although lactacystin is considered an irreversible proteasome inhibitor, its adduct is slowly 
water hydrolyzed (t1/2 ~20hr). Lactacystin is the least stable of the proteasome inhibitors and exists 
in vivo in equilibrium with lactathione, its glutathione reaction product 51. Despite this drawback, 
the high proteasome selectivity makes lactacystin a viable proteasome inhibitor for investigating 
the role of the proteasome in cellular processes.  
II.B.5. Vinyl sulfones. Peptide vinyl sulfones are a class of irreversible proteasome inhibitors. 
Peptide vinyl sulfones also inhibit cysteine proteases (e.g. cathepsins), but changing the 
functional groups in the inhibitor’s peptide portion can modulate their specificity 153. For example, 
replacing the benzyloxycarbonyl (Z) group with the 3-nitro-4-hydroxy-5-iodophenylacetate (NIP) 
group in ZLVS (Z-Leu3-VS) generates NLVS significantly reducing inhibition of cathepsins B and 
S 51. Peptide vinyl sulfones are easy and inexpensive to synthesize, and their irreversible binding 
makes them attractive as protease activity probes. Peptide vinyl sulfones are commonly labeled 
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with fluorophores, biotin, or a radioactive moiety, and specific uses as proteasome activity probes 
are discussed in Part III. Interestingly, vinyl sulfones are more potent and more trypsin-like site-
selective inhibitors than epoxyketones with an identical peptide sequence 154, a feature exploited 
in the development of β2 specific proteasome inhibitors, as discussed in Part IV.   
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II.C. Considerations for proteasome inhibitor design  
In this section we review the structural features that have been exploited to design specific 
inhibitors of the 20S catalytic sites. 
II.C.1. Substrate binding pockets. All six proteasome catalytic subunits (constitutive and 
immune) have a similar substrate binding site topology, in which the S1 position is buried in the 
subunit next to the threonine, the S2 is solvent exposed, and both the catalytic subunit and its 
neighbor contribute to the S3 binding position 155 (Figure 4B). However, residues that make up 
the S1 and S3 sites have very different catalytic subunit properties. Modification of the P1 and P3 
sites on a proteasome inhibitor can significantly alter their subunit specificity and affinity. The β5c 
prefers a small hydrophobic group in P1 and a large hydrophobic group in P3, whereas β5i favors 
the inverse arrangement 64. Therefore, altering the hydrophobic group size in P1 and P3 confers 
selectivity for β5c or β5i. Due to solvent exposure in the P2 position, it can accommodate a range 
of moieties without affecting proteasome binding and is often the site for modifications aimed at 
improving inhibitor solubility and stability. P2 is also a useful attachment site for fluorescent 
probes, biotin tags, or azide handles (discussed further below).  
II.C.2. Structural analysis of bound inhibitors. Knowledge of protein structure and its 
interaction with ligands, guides drug discovery and design. X-ray crystallography is an excellent 
method for obtaining high resolution proteasome structures in complex with inhibitors and has 
been instrumental in understanding proteasome function and advancing proteasome inhibitor 
development 62. The early structures of ALLN and lactacystin bound proteasomes provided clues 
as to the threonine catalytic mechanism and intermediate states 62. The structures of a substrate 
analog bound proteasome showed long range allosteric changes that occur upon substrate 
binding in the active site. The inhibitor-bound structure can be used together with biochemical 
data for structure-activity relationship (SAR) studies and subsequent lead compound optimization.  
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There are drawbacks to using crystallography to study proteasome inhibitor - proteasome 
interactions. First, solvent conditions and inhibitor concentrations used in co-crystallization are 
not physiological and should be considered when interpreting the resultant structure. 20S 
proteasome crystals are usually soaked in solutions with high inhibitor concentrations under 
conditions that preserve crystal integrity, whereas enzymatic assays are carried out at 37oC with 
low inhibitor concentrations and proteasomes under conditions optimized for substrate 
degradation. Discordant data in the yeast 20S proteasome structure in complex with Ac-LLN-al 
showed the inhibitor bound to all six proteasome active sites, but the biochemical data indicated 
that Ac-LLN-al proteasome inhibitor preferentially inhibits the β5 site (with very low activity against 
the β1 and β2) unless used at extremely high concentrations 64. If one considers that most 
proteasome inhibitors affects multiple active sites at high concentrations and that proteasome 
inhibitor concentration in the crystallization condition was in the millimolar range, it is unsurprising 
that the inhibitor bound all sites. This example illustrates the necessity to carefully consider 
existing biochemical data when interpreting new structures.  
Additionally, obtaining good diffraction data relies on homogenous crystal packing. Under these 
conditions, one may miss larger scale conformational changes that take place upon 20S 
proteasome ligand binding. The inherent drawbacks in crystallography methodology highlight the 
need to incorporate other structural methods into understanding the proteasome. Recent 
advances in cryo-electron microscopy (EM) and single particle analysis make it possible to obtain 
near atomic level resolution protein structures in more physiological conditions 156. Proof of 
principle for the cryo-EM utility in structure-based drug discovery and development is found in 157. 
Recently, the noncovalent reversible asparagine-ethylenediamine (AsnEDA)-based inhibitor 
bound human immuno-proteasome cryo-EM structure was used in SAR studies 157. Exploiting 
β5c/β5i residue differences near the S1 pocket improved PKS21187 affinity for β5i down to 15 
nM (from 58 nM) and successfully improved selectivity (20 fold) over β5c 156. Although cryo-EM 
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typically cannot provide quite the same resolution as crystallography, the 20S core particle 
characteristically has high local resolution (~3Å, in both above studies) at the interior of the β 
subunits, making this a valuable method for investigating proteasome ligand binding under 
relatively physiological conditions.  
It is important to keep in mind that cryo-EM structures are derived from averaging classes of 
particles, meaning that protein sub-conformations may be overlooked. This is important in 
interpreting 26S proteasome structures because the complex undergoes large-scale 
conformational changes during cycles of substrate binding and ATP hydrolysis, resulting in many 
conformational states coexisting simultaneously. Despite physiologically relevant conditions, 
conformer subpopulations may not be apparent. For example, Baumeister and colleagues 
published 26S proteasome in the ATP-hydrolyzing state 74 and the ATP-γS bound cryo-EM 
structures 72. However, when they performed a deep classification of more than 3 million 26S 
proteasome particles in the presence of both ATP and ATP-γS they identified a third state of the 
26S proteasome that was believed to be an intermediate conformation during the ATP hydrolysis 
cycle 158. Additional intermediate 26S conformations states have been identified in humans and 
yeast using cryo-EM 159–161. 
II.C.3. Proteasome inhibitor pharmacophore properties. As previously discussed, 
pharmacophores confer specific proteasome inhibitor properties including compound stability, off 
target protease inhibition, and inhibition kinetics. Interestingly, the pharmacophore nature is 
suggested to influence proteasome inhibitor active site specificity.  Epoxyketone warhead 
replacement with vinyl sulfone moieties in β5 inhibitors further improves β5 site (but not β5i site) 
selectivity 153. Therefore, each warhead confers unique properties to the proteasome inhibitor and 
thus careful considerations needs to be made when selecting a pharmacophore along with 
appropriate controls. 
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III. Methods for pharmacological proteasome research 
Extensive methodology exists for investigating proteasome function in vitro and in vivo. Here, we 
describe some commonly used methods for proteasome purification, peptidase activity assays, 
and protein degradation assays in vitro and in cell culture, and discuss their advantages and 
limitations.  
III.A. Proteasome purifications 
Rigorous and reproducible studies of proteasome pharmacology require a source of pure and 
active proteasomes. The following is a summary of methods for endogenous and affinity tagged 
proteasome purifications.  
III.A.1 Endogenous proteasome purification. Endogenous proteasomes are purified from a 
variety of tissues using a series of anion exchange chromatography columns. After purification, 
20S and 26S proteasomes are separated by gel filtration or glycerol gradient centrifugation. 
Because 26S proteasomes require ATP hydrolysis to remain intact, omitting ATP from the 
homogenization and chromatography buffers enriches for 20S proteasomes. Rabbit skeletal 
muscle and bovine liver have abundant proteasomes making it possible to obtain pure 
proteasomes (>95%) in milligram quantities in under a week. Most 20S proteasome preparations 
still use this method today.  
Another method to purify endogenous 26S proteasomes from almost any tissue or cell type takes 
advantage of the 19S regulatory particle’s affinity for proteins containing ubiquitin-like (UBL) 
domains 162. Recombinant glutathione S-transferase (GST) fused to the ubiquitin-like (UBL) 
domain of ubiquitin shuttling factor RAD23B is purified from E. coli and bound to glutathione 
beads. 26S proteasomes in cell or tissue lysates bind the GST-UBL column while all other cellular 
proteins are washed away. Bound 26S proteasomes are subsequently eluted by adding high 
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concentrations of a tandem ubiquitin-interacting motif (UIM) derived from the 19S ubiquitin binding 
subunit, Rpn10 162162. Unlike anion exchange chromatography (which takes ~3 days), the UBL-
affinity method is completed in a single day without high salt buffers. Rapid and gentle 26S 
purification is essential to retain loosely associated proteasome proteins which are lost during 
anion exchange chromatography.  
Because the GST-UBL bait occupies UBL binding sites on the 19S, endogenous UBL domain 
containing proteins and Ub-conjugates may be dislodged from the proteasome upon purification 
163. Despite this limitation, the UBL-affinity method has been valuable in studies investigating 26S 
proteasome composition in a variety of physiological and disease states. For example, Qiu et al., 
(2006) used the UBL-affinity method to identify Rpn13 164, a novel human 19S subunit that tethers 
and activates UCHL5 (a deubiquitinase) to the 26S proteasome and functions as a ubiquitin 
receptor 165. The UBL-affinity method also co-purifies other important proteasome associated 
proteins with important roles in regulating proteasome function and Ub-conjugate degradation 
(e.g. the deubiquitinase USP14) 163. A significant advantage of the UBL-affinity method is that you 
can purify proteasomes from diseased tissues and study the changes in proteasome activity and 
composition without genetic alterations.  
Most commercially available 20S and 26S proteasomes are purified from mammalian (e.g. 
human, rabbit) erythrocytes. Since erythrocytes lack nuclei, these endogenous proteasomes are 
"aged", perhaps with oxidative damage, and may have lower basal activity than those derived 
from nucleated cells. 
III.A.2 Affinity-tagged proteasomes. Several groups have created human cell lines and yeast 
strains stably expressing affinity tagged proteasome subunits to rapidly isolate proteasomes for 
structural and functional studies. Affinity tags are often appended to the C-termini of Rpn11 or β4 
 37 
because modifications on these subunits do not cause any discernable effect on proteasome 
function in cellular or yeast cultures.  
Affinity-tagged proteasome purifications are especially useful for studies of changes in 26S 
proteasome composition because they typically co-purify with more Ub-conjugates and additional 
proteasome-interacting proteins than UBL-affinity or ion exchange chromatography methods. For 
example, Leggett et al., (2002) used a TEV-protease cleavable Protein A derived tags on Rpn11, 
Rpt1, and β4  to study how proteasome interacting proteins (PIPs) regulate the stability of the 
yeast 26S complex in vivo 167. The high purity and yield of affinity-tagged proteasomes is well 
suited for cryo-EM studies. For example, Matyskiela et al., (2013) used cryo-EM analysis of 
Rpn11-3xFLAG yeast proteasomes to study the conformational dynamics during 26S substrate 
engagement 75. Affinity tags are also amenable to high purification efficiency of crosslinked 
complexes under fully denaturing conditions. Guerrero et al., (2006) designed a tandem affinity 
tag consisting of a hexahistidine sequence and an in vivo biotinylation signal (HB) 168. Tandem 
affinity purification of Rpn11-HB proteasomes after in vivo cross-linking was combined with 
tandem mass spectrometry (MS) and quantitative SILAC (stable isotope labeling of amino acids 
in cell culture) to globally map the 26S proteasome interaction network in yeast 168. A TEV-
cleavable version of the HB tag (HTBH and HBTH) allows for one-step purification of human 26S 
proteasomes. Wang et al., (2017) generated several stable HEK293 cell lines expressing tagged 
subunits (e.g. Rpn11-HTBH, HBTH-Rpn1, HBTH-Rpt6) 170. They used these cells lines with in 
vivo and in vitro crosslinking-MS workflows and cryo-EM approaches to comprehensively 
examine protein-protein interactions within the 26S proteasome 169. Choi et al. (2016) developed 
stable β4-HTBH/α3-FLAG and β4-HTBH/α3ΔN-FLAG HEK293 cell lines 171. The α3 N-terminal 
deletion (α3ΔN) results in a constitutively open gate. These cell lines are an excellent tool for 
investigating the role of dynamic proteasome gating, and are discussed further in Part V. It is 
worth noting that most of these cell lines stably express the tagged subunit in addition to the 
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endogenous gene, thus purification does not isolate all proteasome complexes and may not 
reflect all changes in proteasome composition under different physiological states or drug 
treatments. 
III.A.3. Immunoproteasomes. Immunoproteasome preparations are usually purified from 
spleens and cell cultures treated with IFN-γ to increase immunoproteasome subunit expression. 
Immunoproteasomes can be purified using the same anion exchange chromatography methods 
as described above for constitutive proteasomes. However, constitutive proteasomes are 
ubiquitously present in all tissue types and even low amounts can interfere with 
immunoproteasome-specific research. Dechavanne et al., (2013) report that hydrophobic 
interaction chromatography can successfully separate immunoproteasomes from residual 
constitutive proteasome contamination after purification 172.  
III.A.4. Validating and storing proteasome preparations. It is imperative to check for 
contaminating proteases in all proteasome preparations. For example, the anion exchange elution 
profile of tripeptidyl-proteases (TPP) overlaps with proteasomes. TPP is a serine protease and 
capable of cleaving fluorogenic peptides (e.g. Suc-LLVY-amc, Ac-AFF-amc). Proteasome specific 
activity can be verified with proteasome inhibitors as a negative control.  
Regardless of the purification method, it is necessary to confirm the 20S/26S proteasome 
assemblies in your preparation. For example, purifying affinity tagged RPN11 proteasomes will 
select for single capped 20S, double capped 20S, and free 19S particles, while affinity tagged 
20S subunits selects for free 20S, 26S, and 20S associated with other regulators (e.g. PA28, 
PA200). 20S proteasomes and 20S bound to regulators are clearly separated by native-PAGE 
(e.g. NuPAGE® 3-8% tris-acetate gel) 162. Electrophoresis with 26S proteasomes are performed 
at 4oC with adequate ATP and MgCl2 in the buffer to prevent complex dissociation (Table 1). After 
electrophoresis peptidase activity of proteasome complexes is measured by an in-gel 
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fluorescence activity assay 162. The gel is incubated at 37oC in buffer containing the fluorogenic 
peptide substrate Suc-LLVY-amc and the cleaved amc fluorophore is visualized with ultraviolet 
light. Adding 0.02% sodium dodecyl sulfate the gel incubation buffer enhances 20S peptidase 
activity and improves visualization of the 20S band. After UV imaging, the gel can be processed 
with coomassie/silver stain, analyzed by 2D native-SDS-PAGE, or transferred to a membrane for 
immunoblot analysis. Due to the large size of the proteasome complexes (700kDa-2.4MDa), 
incubating the gel in SDS buffer prior to transfer may improve transfer efficiency and increase 
epitope availability. Roelofs et al., (2018) provide methods for various downstream analyses to 
investigate the activity and composition of proteasome complexes separated by native-PAGE 173.  
The association between the 19S and 20S is labile and sensitive to changes in temperature and 
presence of nucleotides. To support integrity of 26S proteasome complexes, purification should 
be performed as rapidly as possible in the presence of adequate ATP and MgCl2 and always at 
4oC. Addition of glycerol (~10%) in the proteasome purification and storage buffers stabilizes the 
26S complexes and the latent 20S gate. After purification, both 20S and 26S proteasomes should 
be flash frozen in liquid nitrogen, stored at -80oC, and never refrozen once thawed. It is important 
to thaw frozen 26S proteasomes on ice and use them immediately after thawing. Since freezing 
and storage conditions can affect the labile 26S proteasome assembly, we recommend verifying 
the assembly state of your 26S preparation after thawing with native-PAGE.  
III.B. Monitoring proteasome activity  
There are numerous methods for monitoring proteasome activity in vitro and in vivo. In vitro 
experiments are performed with either peptide-based or protein-based model substrates. The 
following section covers commonly used peptide and protein-based model proteasome substrates 
and methods for monitoring their degradation. Lastly, we will discuss artificial proteasome 
substrates for expression in cell culture and transgenic animals. 
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III.B.1. Peptide-based model substrates: In vitro proteasome activity is often measured using 
a fluorescent substrate enzyme activity assay. Peptide substrates are useful for monitoring 
proteasome gating and peptidase activities and are amenable to high throughput formats. Model 
peptide substrates are short tri- or tetrapeptides with a C terminal fluorophore (e.g. 7‐amino‐4‐
methylcoumarin, amc). The amino acid sequences are designed to preferentially interact with and 
be degraded by specific 20S subunits (Table 2, Figure 2B). Common peptide substrates are Suc-
LLVY-amc (Succinyl-leucine-leucine-valine-tyrosine-amc), Boc-LRR-amc (Tert-butoxycarbonyl-
leucine-arginine-arginine-amc), and Ac-nLPnLD-
aminoluciferin (N acetyl-norleucinal-proline-norleucinal-
aspartate-amc) for the β5 chymotrypsin-like, β2 trypsin-
like and β1 caspase-like activities, respectively. However, 
it is important to note that at high substrate concentrations 
multiple active sites can participate in substrate cleavage. 
The amc moiety is quenched at the excitation wavelength 
(ex: 380nm) when attached to the peptide, and proteolytic 
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cleavage enhances fluorescence (em: 460nm). Changes in fluorescence intensity are monitored 
in real time using a microplate reader. The increases in fluorescence intensity is directly 
proportional to proteasome proteolytic activity. This assay is rapid and suitable for high-throughput 
studies. Cell-based reagent kits use similar aminoluciferin-fused peptide substrates which allows 
measurement of proteasome peptidase activity in intact cells.  
Although fluorescent substrate peptides are an excellent tool for preliminary studies measuring 
proteasome activity (e.g. screening compound libraries), there are several pitfalls. Foremost, 
small peptides bypass the need for 19S recognition and unfolding and thus report on only 20S 
peptidase activities. Furthermore, changes in peptide hydrolysis does not necessarily correlate 
with changes in protein degradation, and it is important to note that at high peptide substrate 
concentrations multiple active site types can participate in peptide cleavage. As such, 
chymotrypsin-like (β5) activity (Suc-LLVY-amc) assays evaluating response to a proteasome 
inhibitor may overestimate the reduction in protein degradation in vivo. Therefore, it is imperative 
to evaluate the experimental effects with full length protein degradation and not rely solely on 
peptide hydrolysis data.  
III.B.2. Protein based model substrates. Many protein substrates are available for monitoring 
20S and 26S proteasome degradation in vitro (e.g. using purified proteasomes or cellular lysates). 
Here we describe methods for quantitating protein degradation and give examples of model 
substrates for 20S and 26S proteasome activity. 
Methods to quantitate protein degradation. The extent of in vitro protein degradation can be 
measured in several ways. The fluorescamine assay is a quantitative method for measuring 
protein cleavage products generated by the proteasome. The proteasome processively degrades 
proteins and the products generated equals the number of substrate molecules degraded 
multiplied by the mean number of cuts made in a single polypeptide 152. Fluorescamine addition 
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to an amine free assay buffer quickly labels new N-termini amines on short peptides generated 
by proteolytic cleavage.  
Alternatively, the proteins can be separated by SDS-PAGE and monitored for substrate band 
disappearance via coomassie staining, silver staining, or immunoblot. Care must be taken when 
monitoring degradation via western blot, as degradation of the epitope results in complete loss of 
signal, which may not corollate with complete protein degradation. Since most gel-based protein 
degradation assays are performed with small reaction volumes (<20 µL) incubated in centrifuge 
tubes, the amount of substrate remaining should be normalized to a loading control (e.g. a 20S 
proteasome subunit) to control for loss of substrate protein during pipetting or incubation steps. 
Fluorescence anisotropy is useful to follow the degradation of fluorescent dye labeled protein 
substrates of 20S and 26S proteasomes in real time 174,175. Bhattacharyya et al. (2018) describe 
methods for high throughput measurement of 26S ubiquitin-dependent degradation using dye 
labeled substrates 174.  
20S substrates (19S independent). For example, β-casein is a good substrate for monitoring 20S 
protein degradation since it is unstructured, thus abrogating the requirement for the unfoldase 
activity associated with the 19S regulatory particle and is commercially available.  
26S (ubiquitin independent) substrates. Folded substrates are required to determine the 
contribution of 19S activities toward 26S proteasome degradation. Ornithine decarboxylase 
(ODC) is a stably folded protein containing a C-terminus degradation tag 176 that promotes rapid 
Ub-independent degradation by 26S proteasomes 177. Fusing the ODC degradation tag (cODC) 
to other proteins promotes their proteasomal degradation 178. For example, cODC fusion to the 
titin I27 domain allows for testing of the ubiquitin-independent degradation of a folded protein, 
though the kinetics may be slow 179. Destabilizing mutations can be introduced to I27 and 
accelerate substrate degradation 179.  
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26S (ubiquitin dependent) substrates. The 26S ubiquitin-dependent degradation of folded 
proteins can be monitored with a tetra-ubiquitin fused green fluorescent protein (GFP) 180 with a 
c-terminal unstructured region 181 or a tetra-ubiquitinated dihydrofolate reductase (DHFR) 182. It is 
also possible to express some cODC fusion proteins in vivo to monitor proteasome activity.  
III.B.3. Proteasome activity in cell culture. The 26S proteasome degrades ubiquitinated 
proteins and proteasome impairment leads to poly-ubiquitinated protein accumulation. Measuring 
changes in high molecular weight poly-ubiquitin protein conjugates via immunodetection is a 
method to monitor changes in proteasome activity. This is a general, non-specific method to 
measure changes in proteasome degradation and should not be used alone to assess 
proteasome activity. 
Stable expression of GFP-fusion reporters is commonly used in cell culture to monitor proteasome 
activity. Measuring fluorescent reporters is a well-established technique for monitoring 
proteasome activity. Changes in reporter protein levels (in the absence of translation changes) 
inversely reflects degradative capacity of the UPS. Wild type GFP has a long half-life in 
mammalian cells and therefore is not a suitable proteasome degradation substrate for most 
experiments. Several GFP-fusion proteins have been engineered as specific proteasome 
substrates (Table 3). Bence et al. (2005) designed a synthetic reporter consisting of the short 
degron, CL1 183, a consensus sequence for ubiquitination that was first identified in fission yeast 
184, fused to the C-terminus of GFP (GFPu), thereby targeting it for ubiquitin-dependent 
proteasome degradation 183. Addition of the CL1 degron converted the GFP half-life from ~10 
hours to ~30 minutes. Cell compartment-specific proteasome function can be monitored by 
localization of GFPu directed to the nucleus (NLS- GFPu), the cytoplasm (NES-GFPu) 183,185, or to 
neuronal synapses (PSD95- GFPu and SNAP25- GFPu) 186 (Table 3).  
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Other UPS reporters have been generated to determine targeted proteasome degradation using 
different pathways. The N-end rule relates the cellular protein half-life to the identity of its N-
terminal residue 187.  Fluorescent substrates of the N-end rule degradation pathway have been 
created with ubiquitin-GFP fusion constructs. When these ubiquitin fusion proteins are expressed 
in cells, deubiquitinases rapidly cleave the ubiquitin and expose an unmodified N terminal GFP 
residue. N terminal arginine residue exposure (e.g. the substrate Ub-R-GFP) recruits UBR E3 
ligases which ubiquitinate the protein, targeting it for proteasome degradation 188. Techniques for 
generating ubiquitin fusion proteins with varying half-lives and conditional mutants are described 
in 189,190. Unlike Ub-R-GFP, the reporter UbG76V-GFP cannot be deubiquitinated (thereby 
bypassing the N-end rule pathway) and is a model substrate for the in vivo Ub fusion degradation 
(UFD) pathway 188. The T cell receptor protein α chain is rapidly degraded in nonhematopoietic 
cells, and a TCRα-GFP fusion protein can monitor ERAD specific proteasome activity 191. Protein 
synthesis also influences the steady state protein levels, and synthesis rates can be affected by 
cellular stress, transfection efficiency, and varies from cell to cell. Therefore, it is imperative to 
utilize appropriate experimental design to take expression and translation differences into account 
when monitoring protein degradation. Commonly used methods are pulse-chase experiments, 
cycloheximide chase experiments, bicistronic constructs, or the parallel measurement of stable, 
long lived fluorescent reporters. Lastly, each substrate only illustrates a single degradation 
pathway, which may or may not accurately reflect the UPS perturbations within a cell. It is 
advantageous to consider the use of multiple such proteasome substrates to confirm findings.  
In addition to cellular proteasomal activity, proteasome localization and dynamics can also be 
monitored with fluorescently labeled proteasome subunits. Both α and β subunits can be fused to 
a fluorescent protein and have been shown to efficiently incorporate into proteasome particles. 
For example, α4-YFP 192 and a CFP-tagged β1i 193 have been used to monitor localization 
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dynamics of constitutive and immunoproteasomes in living cells. Detailed methods for monitoring 
proteasome dynamics in living cells are described elsewhere 194.    
 
III.B.4. In vivo proteasome activity. Transgenic animals that carry UFD proteasome substrates 
have also been generated and are used to study proteasome function in live tissues 195,196. 
Detailed methods for monitoring UFD protein degradation in yeast, cell lines, and transgenic mice 
are described in Menendez-Benito et al. (2005) 197. The photoactivatable UbG76V-dendra2 
construct monitors proteasome activity independent of translation and has been successfully used 
in transgenic C. elegans to determine tissue specific proteasome degradation rates 198.  
III.C. Proteasome active site probes  
Activity based probes (ABP) recognize catalytic sites on the constitutive or immuno-proteasomes 
without requiring genetic techniques. Most proteasome ABP probes are modified proteasome 
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inhibitors with a fluorescent molecule incorporated at or near the N-terminus. ABPs have been 
developed that can distinguish specific constitutive and immunoproteasome subunits 199. After 
proteasome labeling and SDS-PAGE protein separation, the modified proteasome subunits are 
immediately visualized via in-gel fluorescence or immunoblotting. Furthermore, cell permeable 
ABPs are compatible with live-cell imaging to detect real-time proteasome localization or flow 
cytometry-based experiments. Site selective ABPs are useful in determining novel proteasome 
inhibitor subunit specificity. A recent review provides a detailed account of currently available 
APBs196.  
IV. Proteasome inhibitors to treat human disease 
IV.A. Hematological Malignancies  
IV.A.1. Bortezomib & Multiple Myeloma. At therapeutic doses, bortezomib inhibits 
approximately 30% of proteasome mediated protein degradation 146, which is sufficient to induce 
MM tumor cells apoptosis without causing general toxicity in non-transformed cells. Considering 
the indispensable role of proteasome function in all cell types this raises an important question: 
why is bortezomib particularly toxic to MM cells? First, proteasome inhibition stabilizes the NF-κB 
complex in the cytoplasm and reduces NF-κB dependent gene expression. MM cells have 
increased NF-κB activity and rely on this pathway for survival and proliferation 200. Furthermore, 
NF-κB activity generates more pro-inflammatory NF-κB activators in a positive feedback loop, 
therefore partial proteasome inhibition is sufficient to reduce this pathological cascade 201. 
Bortezomib-mediated NF-κB inhibition enhances the anti-MM conventional chemotherapeutic 
agents (e.g. dexamethasone, lenalidomide) effects and increases MM patient progression-free 
survival (PFS) and overall survival (OS) 151. Second, proteasome inhibition reduces misfolded 
protein clearance. MM arises from mature immunoglobulin (Ig)-secreting plasma cell hyper 
proliferation in the bone marrow and MM cells have a high rate of Ig production. Immunoglobulins 
are large multisubunit molecules synthesized and folded in the ER where they are post-
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translationally modified prior to secretion. The high Ig production rate and multiple modifications 
make MM cells heavily reliant on the proteasome and ERAD to maintain ER homeostasis 202 – so 
it reasons they will be more sensitive to proteasome inhibition. Accordingly, treatment of MM cells 
with proteasome inhibitors results in a toxic misfolded protein buildup activating JNK and 
eventually resulting in apoptosis. Third, proteasome inhibition stabilizes various tumor suppressor 
proteins (e.g. p27, p53) and prevent cell cycle progression 203.  
IV.A.2. Bortezomib Resistance. Although bortezomib revolutionized the treatment for MM, 
bortezomib resistance and relapse often occurs in patients who initially respond to bortezomib. 
Therefore, bortezomib resistance is a major issue for MM therapy. There are several mechanisms 
linked to bortezomib resistance and they fall into two broad categories. First, there are changes 
in proteasome subunit composition and expression 204. Additionally, mutations in the β5 
bortezomib binding pocket are associated with bortezomib resistance in MM cell lines 205. 
However, the same mutations have not been confirmed in MM patients resistant to bortezomib 
treatment. Bortezomib-resistant MM cells also display transcriptome alterations including 
increased anti-apoptotic protein and decreased pro-apoptotic protein expression 206. For example, 
bortezomib-resistant MM cells have higher Bcl-2 family 207, and heat shock protein (Hsp27, 
Hsp70, and Hsp90) expression, which are expected to mitigate the misfolded protein burden in 
these cells.   
Other extrinsic factors contribute to bortezomib-resistance. Not surprisingly, the bone marrow 
microenvironment plays an important role in supporting bortezomib-resistance. Bone marrow 
stem cells (BMSC) isolated from bortezomib-resistance MM patients have different cytokine 
profiles than BMSCs from bortezomib-sensitive MM patients 208. Several specific pro-survival 
cytokines and microRNAs are upregulated and contribute to bortezomib-resistance 209. 
Interestingly, bortezomib-resistant patient BMSCs confer resistance to proteasome inhibitor -
naïve MM cells, whereas proteasome inhibitor -naïve MM cells co-cultured with bortezomib-
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sensitive MM patient BSMCs respond to subsequent bortezomib exposure 209. Elucidating specific 
microenvironment mechanisms supporting bortezomib-resistance is expected to identify 
additional targets for combination therapies to enhance proteasome inhibitor sensitivity in RRMM 
patient.  
IV.A.3. Bortezomib Dose Limiting Toxicity. The primary dose limiting bortezomib treatment 
toxicity is peripheral neuropathy (PN). Bortezomib induced PN typically affects the peripheral 
nervous system sensory fibers and is associated with a painful burning sensation, numbness, 
and/or tingling in the extremities. Clinical trials report  bortezomib-induced PN incidence (all 
grades) between 30-60% 210 and grade ≥3 occurring between 2-23% 211. PN is a major cause of 
dose reduction or discontinuation in patients and overcoming this limitation is a significant 
challenge to clinicians and pharmaceutical development. Recent clinical trials demonstrated that 
patients receiving alternative dosing schedules (i.e. once weekly, instead of bi-weekly) or 
subcutaneous injection of bortezomib (instead of IV) had a lower incidence of PN, without 
changes in efficacy. For patients with intolerable PN, these options constitute another avenue of 
hope before discontinuing treatment 211.  
Although the exact molecular mechanisms by which bortezomib induces PN are not completely 
clear, clinical and experimental evidence points to pathology in the primary sensory neurons cell 
bodies as a major contributing factor. The peripheral nervous system (PNS) encompasses the 
nerve fibers and cell bodies that reside outside the central nervous system (CNS, i.e. brain and 
spinal cord). Sensory receptors in periphery tissues transduce physical stimuli (e.g. pain, touch, 
pressure, temperature) into action potentials which are transmitted via primary sensory neurons 
to the CNS. The primary sensory neuron cell bodies are in the dorsal root ganglion (DRG) just 
outside of the spinal cord. Many in vivo mouse studies and in vitro DRG explant studies of 
bortezomib induced PN demonstrate accumulation of ubiquitinated proteins in DRG soma, 
defects in mitochondrial calcium homeostasis, disrupted mitochondrial axonal transport, 
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alterations in tubulin polymerization and localization, and defects in fast axonal transport due to 
blockage of axonal protein turnover  212–214.  
Why are the DRG neurons especially susceptible to proteasome inhibitor toxicity? Proper CNS 
and PNS neural function requires an exquisitely controlled microenvironment. To this end, the 
blood–neural barrier (BNB) and the blood–brain barrier (BBB) form a protective barrier between 
the changing circulatory milieu and the PNS and CNS, respectively. These intricate barriers 
contain complex tight junction proteins. Unlike the rest of the nervous system, the cell body-rich 
area within the DRG has endothelial fenestrations and lacks tight junction proteins, rendering it 
more permeable to substances in the blood compared to the rest of the nervous system. This 
region is highly vascularized and blood permeability has been observed in human subjects using 
magnetic resonance imaging (MRI) with gadolinium contrast agents 210. While bortezomib cannot 
cross the tight BNB and BBB, it can cross into the cell body-rich region of the DRG and inhibit 
proteasome function. This differential permeability is thought to underlie peripheral sensory 
system vulnerability to cytostatic agents used in chemotherapy (e.g. bortezomib) compared with 
other neurons in the CNS 210.  
Arastu-Kapur et al. (2011) suggest bortezomib induced neurotoxicity is due to mitochondrial 
serine protease, HtrA2/Omi, inhibition and independent of proteasome inhibition 215. They also 
showed that a second-generation proteasome inhibitor, carfilzomib, did not inhibit HtrA2/Omi in 
this study. The authors conclude that proteasome inhibitor induced neurotoxicity is due to off-
target bortezomib effects, and not generalizable to the proteasome inhibitor class. However, two 
subsequent independent studies failed to show bortezomib-mediated HtrA2 inhibition 216,217. 
Carfilzomib is associated with less severe PN than bortezomib, however, the role of HtrA2 or 
other off target effects in proteasome inhibitor induced PN remains to be determined.  
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IV.A.4. Bortezomib Efficacy in Solid Tumors. Despite bortezomib’s clinical efficacy in treating 
hematological malignancies, it has had limited success in clinical trials for solid tumors. This may 
arise from poor bortezomib tissue penetration (at the doses used in MM) and rapid clearance from 
the blood 218. Dosage cannot be increased to overcome poor tissue penetration due to increased 
risk for PN.  Second generation proteasome inhibitor are in development to overcome these 
limitations of bortezomib. Ongoing clinical trials are evaluating combinations of chemotherapy and 
radiotherapy with bortezomib in a search for new synergistic drug combinations.   
IV.B. Second Generation proteasome inhibitors 
Bortezomib treatment efficacy in human cancer renewed interest in developing other novel 
proteasome inhibitors to overcome bortezomib limitations. Two second generation proteasome 
inhibitors, carfilzomib (2012) and ixazomib (2015), are FDA approved for relapsed-refractory MM 
patients. Carfilzomib and ixazomib are well tolerated in heavily pretreated patients and show 
effectiveness in bortezomib-resistant cases 211. Importantly, most cases of PN with carfilzomib 
and ixazomib are low grade and usually do not worsen preexisting PN resultant from previous 
bortezomib treatment 211. Schlafer et al. (2017) provide a detailed review of the bortezomib, 
carfilzomib, and ixazomib clinical trials. Here we highlight second-generation FDA approved PIs 
and selected newer PIs undergoing preclinical evaluation in hematological cancers, solid tumors, 
and autoimmune disorders208. Our list of proteasome inhibitors is not intended to be 
comprehensive, but to rather increase familiarity with these important aspects. Table 4 lists 
important properties of first- and second-generation proteasome inhibitors in clinical trials.  
 IV.B.1. Carfilzomib. Carfilzomib (Kyprolis®) is the second FDA approved proteasome inhibitor. 
Carfilzomib is used as a single agent or in combination with immunomodulatory agents in RRMM 
patients who have received one to three prior therapies, including other proteasome inhibitors 219. 
Carfilzomib has a tripeptide backbone containing phenylalanine, leucine, and homophenylalanine 
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with a terminal epoxyketone group that forms an irreversible covalently bond with the proteasome 
catalytic threonine 220. As with epoxomicin, the carfilzomib epoxyketone warhead forms a dual 
covalent adduct with the active site threonine, which greatly reduces the off targets. 
Importantly, carfilzomib provides some therapeutic benefit for RRMM patients who relapse after 
bortezomib treatment, while also rendering less neurotoxic side effects 211,219. The ENDEAVOR 
phase III clinical trial compared bortezomib plus dexamethasone versus carfilzomib plus 
dexamethasone in a cohort of newly diagnosed MM patients. ENDEAVOR reported significantly 
higher incidence of ≥2 PN in the bortezomib group (32%) vs. 6% in the carfilzomib group 221. This 
was the first head to head comparison between bortezomib and carfilzomib patients. 
Unfortunately, drug resistance is observed following carfilzomib treatment in a small subset of 
patients 222. Although the resistance mechanism is not fully elucidated, studies suggest that 
increased expression of drug efflux pump P-glycoprotein (P-gp, a known transporter of 
carfilzomib) in carfilzomib-resistant cells contributes to the resistant phenotype 223. However, more 
detailed studies are needed to confirm this resistance mechanism.  
Carfilzomib also shows therapeutic promise in several preclinical models of solid tumors. 
Carfilzomib effectively sensitized tumor cells to doxorubicin induced apoptosis in several in vivo 
preclinical solid tumor models including neuroblastoma and colon cancer 224,225. Many doxorubicin 
(dox) resistant tumor cells have upregulated NF-κB activity that promotes survival 226,227, 
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suggesting combination treatment with a proteasome inhibitor may be effective at overcoming 
dox resistance. Although the exact mechanisms are unknown, it is thought that carfilzomib-
mediated NF-κB inhibition sensitizes tumor cells to doxorubicin. Based on these preclinical 
studies, carfilzomib (in combination with other chemotherapy drugs) is currently undergoing phase 
I and II clinical trials in advanced solid tumors, renal disease, transplant rejection, and 
hematological malignancies (clinicaltrials.gov).   
IV.B.2. Ixazomib. Bortezomib and carfilzomib are administered intravenously, requiring patients 
to visit a clinic several times over the course of their treatment. Ixazomib (MLN9708, Ninlaro®) is 
the first and only orally bioavailable PI FDA approved for RRMM treatment 228. Ixazomib was 
developed through a large-scale boron-containing PI screening for compounds with 
physiochemical properties distinct from bortezomib. Ixazomib is a bioavailable prodrug which is 
hydrolyzed into the active metabolite MLN2238 when exposed to the GI tract and plasma and is 
a potent and reversible β5 proteasome subunit inhibitor 229.   
Despite similarities, there are important distinctions between ixazomib and bortezomib. 
Importantly, clinical trials report a lower incidence of PN in patients treated with ixazomib 
compared to bortezomib, and ixazomib is effective in treating bortezomib-resistant RRMM 
patients 230. In addition, ixazomib demonstrated five times higher drug distribution supported by 
blood volume distribution (Vd), with a Vd 20.2 L/kg for ixazomib vs. Vd =4.3 L/kg for bortezomib 
229. Ixazomib also displays anti-tumor efficacy in solid tumor preclinical models 224. Numerous 
phase I and II clinical trials are underway, evaluating ixazomib treatment in glioblastomas, solid 
tumors, triple negative breast cancer, B cell lymphoma, lupus, bladder cancer, and lymphoma. 
IV.C. Additional proteasome inhibitors in clinical trials. 
IV.C.1. Marizomib. Marizomib (NPI-0052, Salinosporamide A) is a naturally occurring PI isolated 
from the marine actinomycete Salinispora tropica and is under development for MM and 
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glioblastoma (GBM) treatment 231. Marizomib is a γ-lactam-β-lactone which demonstrates unique 
binding and bioavailability profiles, setting it apart from other PIs. Its unusual binding mechanism 
was elucidated using biochemical and crystallography approaches. In contrast to other β-
lactones, marizomib has unique chloroethyl and cyclohex-2-enylcarbinol substituents, giving rise 
to important interactions within proteasome active sites. These unique interactions are thought to 
be responsible for marizomib's high proteasome affinity and specificity 64.  
 Marizomib irreversibly inhibits β5 (IC50 3.5 nM) and β2 (IC50 28 nM) active sites, although it can 
inhibit β1 at higher concentrations (IC50 430 nM) 232.  In vitro and binding competition experiments 
show marizomib binds to all three subunits at clinically relevant doses 229. Unexpectedly, patient’s 
β1 and β2 activities were not affected (in PBMCs) during the first cycle of marizomib treatment 
233. After the second dose cycle, decreased peptidase was observed, but only in packed whole 
blood samples – which contain mostly erythrocytes 233. Whether marizomib inhibits β1 and β2 
activity in nucleated cells that can synthesize new proteins remains to be determined. Importantly, 
marizomib shows the ability to overcome bortezomib and carfilzomib resistance in a limited 
number of RRMM patients 233. Additional trials investigating marizomib in combination with other 
chemotherapy drugs in RRMM are ongoing.   
 Marizomib is the only PI in clinical trials that can permeate the blood brain barrier, making it an 
attractive candidate in CNS malignancy treatment.  In animal studies, marizomib distributed to the 
brain at 30% blood levels in rats and significantly inhibited (>30%) baseline chymotrypsin-like 
proteasome activity in monkey brain tissue 234. Furthermore, marizomib treatment elicited a 
significant antitumor effect in a rodent intracranial malignant glioma model 234 and was well 
tolerated in phase I/II clinical trials for advanced and newly diagnosed glioblastoma. Based on 
encouraging results from phase I and phase II marizomib trials in GBM patients, a phase III trial 
of marizomib in combination with standard temozolomide-based radiochemotherapy for patients 
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with newly diagnosed GBM (clinical trial NCT033450951) is scheduled to begin June 2018. GBM 
is the most common high-grade brain malignancy in adults with a 25% two-year survival after 
standard treatment 235. New therapies are critically needed for these patients. 
IV.C.2. Oprozomib. Efforts to synthesize an orally bioavailable epoxyketone proteasome inhibitor 
led to oprozomib (PR-047, ONX-0912) development. Oprozomib is an irreversible and potent β5c 
and β5i proteasome subunit inhibitor, with an IC50 36 nM and 82 nM, respectively 236. Oprozomib 
oral administration demonstrated anti-tumor activity in MM, squamous cell carcinoma of the head 
and neck, and colorectal cancer preclinical models 237. 
The first phase I study (NCT01365559) with single-agent oprozomib evaluated patients with 
advanced solid tumors. Oprozomib was well tolerated, with low-grade gastrointestinal side effects 
being the most common. Unfortunately, despite dose-dependent increases in proteasome 
inhibition, the best response achieved was stable disease (23% of patients) and no clinically 
meaningful correlates between proteasome inhibition and treatment efficacy were observed. 
Considering this was a heavily pretreated patient population with advanced cancer, the lack of a 
therapeutic response does not necessarily reflect the potential of oprozomib to treat earlier stages 
or other cancers. Clinical studies investigating the oprozomib efficacy in hematological 
malignancies are ongoing. In a phase I/II study (NCT014164282), a new oral oprozomib 
formulation is being investigated, and other studies are investigating oprozomib in combination 
with dexamethasone and lenalidomide.  
IV.D.  Immunoproteasome specific proteasome inhibitors 
Specifically targeting the immunoproteasome could be advantageous over currently approved PIs 
in treating certain diseases. The immunoproteasome is present at low levels in normal cells. In 
                                                            
1 ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Nov 17 -. Identifier NCT03345095 
2
 ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011 Aug 5 -. Identifier NCT01416428 
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contrast, some cancers (including MM), inflammatory diseases, and autoimmune diseases have 
increased immunoproteasome subunit expression  238. It is thought that selective 
immunoproteasome inhibition may have less adverse effects than broadly acting PIs like 
bortezomib and carfilzomib since certain cell populations would be preferentially affected 239. 
 IV.D.1. ONX-0914. ONX-0914 (PR-957) is an irreversible epoxyketone β5i immunoproteasome 
subunit inhibitor, with minimal cross-reactivity for the constitutive proteasome β5 subunit (β5c). 
Preclinical trials demonstrate β5i inhibition with ONX-0914 attenuates disease progression in 
colorectal cancer  240, rheumatoid arthritis 241, and systemic lupus erythematosus animal models 
242. Importantly, ONX-0914 displays low neurotoxicity without sacrificing efficacy, an effect that 
may be attributed to the selective β5i inhibition 243.  Johnson et al. (2017) synthesized and 
screened ONX-0914 analogues for β2i inhibition. They identified and characterized compound 
KZR-504, a β2i selective proteasome inhibitor. However, KZR-504 displayed poor membrane 
permeability and did not ameliorate cytokine release from stimulated splenocytes 244.  
Another analogue, KZR-616, was well tolerated in a phase I clinical trial in healthy volunteers with 
minimal adverse side effects (Lickliter et al., 20173). KZR‐616 recently entered a phase Ib/II 
clinical trial (NCT033930134) as a single agent treatment for autoimmune‐triggered inflammation 
(systemic lupus erythematosus).  
 IV.E. Novel combination therapies 
Anti-cancer drugs are often administered in combination to synergistically enhance cytotoxicity 
and prevent drug-resistant tumor cell population development. Several known chemotherapy 
resistance mechanisms result from abrogated proteasome activity. For example, NF-κB activity 
                                                            
3
 Lickliter J, Anderl J, Kirk CJ, Wang J, Bomba D. KZR-616, a Selective Inhibitor of the Immunoproteasome, Shows a Promising Safety and Target Inhibition 
Profile in a Phase I, Double-Blind, Single (SAD) and Multiple Ascending Dose (MAD) Study in Healthy Volunteers[abstract].ArthritisRheumatol. 2017; 69(suppl 10 
4 ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 Jan 8 -. Identifier NCT03393013 
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is upregulated in solid tumors that develop chemotherapy (e.g. doxorubicin) or radiation 
resistance and is a driving force behind the resistant phenotype 51. Accordingly, preclinical studies 
with solid-tumor xenograft and cellular models show increased sensitivity to chemotherapy and/or 
radiation induced apoptosis when combined with proteasome inhibitors 245. Several phase I and 
II clinical trials are evaluating PI safety and efficacy in combination with various chemotherapy 
agents in recurrent or refractory advanced cancers.  
 β1 and β2 site upregulation has been reported in tumor cells resistant to bortezomib or carfilzomib 
treatment 51. LU-102 is a peptide vinyl-sulfone β2 specific inhibitor 246 and alone it is toxic to MM 
cells, but it also synergized with β5 inhibitors (bortezomib and carfilzomib) to overcome PI 
resistance in MM cell lines 246. The observed synergy between β5 and β2 inhibitors suggests that 
multiple site-specific proteasome inhibitor combinations may be an effective alternative in PI-
resistant malignancies with reduced risk of adverse side effects.  
V. Novel Proteasome Drug Targets 
V.A. Deubiquitinating enzyme inhibitors 
With three ubiquitin receptors on the proteasome, several shuttling factors, and multiple ubiquitin 
chain types on substrates, the process of substrate recognition by the 26S proteasome is 
incredibly complex and much remains unknown. We briefly summarized the process of ubiquitin-
degradation in Part I and here, will discuss how deubiquitinating enzymes (DUBs) may be 
targeted to treat diseases. Detailed reviews of 26S substrate recognition and processing have 
already been written 77 and 76. 
Three DUBs are associated with the 26S proteasome: Rpn11, Uch37 and Usp14. Rpn11 is the 
only DUB that is an integral part of the 19S regulatory particle. Positioned directly above the 
translocation pore, Rpn11 is a metalloprotease that removes Ub chains at their attachment point 
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(lysine) on the substrate that is committed for degradation 75. Mutations in Rpn11 that disrupt its 
catalytic activity stall ubiquitin substrate degradation and eventually lead to cell death 247. Li et al. 
(2017) recently developed capzimin, a first-in-class selective inhibitor of Rpn11. The Rpn11 active 
site is located within the highly conserved JAMM motif and features a catalytic Zn2+ ion 247. 
Capzimin binds the catalytic zinc ion and prevents Rpn11 activity 248. Remarkably, Capzimin 
treatment stabilized proteasome substrates and blocked proliferation in several tumor cell lines 
248. This anti-tumor activity suggests Rpn11 inhibition may be an effective alternative to active site 
inhibition for treating malignancies. Unlike Rpn11, Uch37 and Usp14 are only transiently 
associated with the 19S regulatory particle 166,249. Uch37 and Usp14 enzymes trim Ub chains 
before the substrate is committed to degradation, which may suppress protein degradation by 
promoting early substrate release 76. Accordingly, loss of Usp14 homologue Ubp6 increases 
substrate degradation by the proteasome 250,251. Despite high affinity, Usp14 easily dissociates 
from 26S complexes during conventional proteasome purification techniques and should be 
considered when designing in vitro experiments 76.   
Enhancing proteasome function has the potential to treat protein misfolding disorders, such as 
neurodegenerative diseases, and Usp14 inhibition may promote ubiquitin-dependent protein 
degradation. To this end, Boselli et al. (2017) developed IU-47, a potent and specific inhibitor of 
Usp14. Inhibition of Usp14 DUB activity by IU-47 promoted proteasome degradation of the 
microtubule associated protein tau (implicated in the pathogenesis of Alzheimer’s disease) in 
neuronal cultures and enhanced resistance to oxidative stress 252. The implications of 
pharmacological proteasome activation will be discussed in the following section. 
V.B. Activation of the 20S by gate-opening 
We highlighted essential functions of the proteasome required for proper neuronal functioning in 
Part I. Then Part II discussed the negative impacts of proteasome inhibition on primary sensory 
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neurons. To bridge these concepts, we will further discuss evidence that supports the proteasome 
as a target for pharmacological activation to treat proteopathies.  
The most common neurodegenerative diseases are characterized by an accumulation of 
aggregation-prone proteins concomitant with a loss of proteostasis, which results in progressive 
death of neurons 121–123. Impaired proteasome function has been implicated, as a primary cause 
or a secondary consequence, in the pathogenesis of many neurodegenerative diseases, including 
Alzheimer’s, Parkinson’s, and Huntington’s disease 47,124–127.  
Soluble forms of aggregated proteins, called oligomers, are implicated in the pathogenesis of 
most neurodegenerative diseases 253,254 and haven been shown to impair proteasome function 
255–260. Our lab recently identified a mechanism in which soluble oligomers of different proteins 
from multiple neurodegenerative diseases allosterically impair the proteasome gate by a shared 
mechanism 175. These toxic oligomers shared a similar three-dimensional conformation 
recognized by the anti-oligomer antibody, A11 261. The A11+ oligomers bound to the outside of 
the 20S cylinder and stabilized the gate in the closed conformation. However, proteasome 
function could be rescued by adding an 8 residue HbYX peptides. The HbYX peptides 
allosterically open the gate and the HbYX motif peptides overcame the oligomer inhibition and 
restored proteasome function 175.  
A recent and popular idea for treating neurodegenerative diseases is enhancing proteasome 
activity to suppress toxicity and related proteotoxic pathophysiology, but to date no drugs are 
available that directly activate proteasome function.  
Since IU-47 exerts its effect upstream of the proteasome gate, it is not expected to function in 
conditions where the proteasome gate is impaired. Choi et al. (2016) generated a HEK293 cell 
line with a stable transfection of a mutant 20S α-subunit (α3∆N) that induces 20S gate opening. 
They showed that HEK293-α3∆N cells had increased degradation of proteasome substrates 
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(including tau protein) and increased resistance to oxidative stress compared to WT 171. While 
serving as a proof-of-principle that opening the proteasome gate can clear aggregation prone 
proteins and increase cell viability, it cannot be determined if pharmacologically activating the 
proteasome in an already diseased state (pre-existing oligomers, aggregates, and oxidative 
stress) can restore cellular proteostasis. Nonetheless, elucidation of a common mechanisms of 
proteasome inhibition is a major step towards the rational design of proteasome activating 
compounds, which may be a promising route to restore proteostasis in diseases. 
Conclusions 
As a highly regulated, multicatalytic macromolecular complex, the proteasome possesses 
multiple drug targets to module its degradation capacity. Proteasome inhibitors helped early 
researchers study the proteasome’s cellular functions. Today, three inhibitors are approved for 
use in the clinic to treat hematological cancers and several more inhibitors (synthetic and 
naturally occurring) are in preclinical and clinical testing.  Fine tuning the pharmacological 
properties of proteasome inhibitors may improve their efficacy for use in solid tumors. The last 
decade has witnessed major progress in our understanding of 26S proteasome structure and 
dynamics. In the coming years, we expect development of new inhibitors and activators of non-
proteolytic components of the 26S proteasome. We anticipate that proteasome activation will 
become a validated target to treat proteotoxic diseases.  
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Protein accumulation and aggregation with a concomitant loss of proteostasis contributes to the 
vast majority of neurodegenerative diseases. Because the ubiquitin-proteasome system (UPS) 
plays a major role in protein degradation and proteostasis we hypothesized that a general mech-
anism of UPS impairment could contribute to neurodegenerative diseases. Here, we show that 
three different proteins from Alzheimer’s, Parkinson’s, and Huntington’s disease that misfold and 
oligomerize into a shared three-dimensional structure potently impair the proteasome. This study 
indicates that the shared conformation allows these oligomers to bind to and inhibit the pro-
teasome with low nM affinity, impairing ubiquitin-dependent and ubiquitin-independent pro-
teasome function in brain lysates. Detailed mechanistic analysis demonstrates that these oligo-
mers inhibit the 20S proteasome through allosteric impairment of the substrate-gate in the 20S 
core particle, preventing the 19S regulatory particle from injecting substrates into the degradation 
chamber. These results provide a novel molecular model for oligomer-driven impairment of pro-
teasome function that is relevant to a variety of neurodegenerative diseases, irrespective of the 







The most common neurodegenerative diseases are characterized by an accumulation of aggre-
gation-prone proteins concomitant with a loss of proteostasis, that results in progressive death of 
neurons1–3. Culminating evidence from the past two decades has revealed that soluble, oligomeric 
forms of protein aggregates (such as A in Alzheimer’s disease, -Synuclein in Parkinson’s dis-
ease, and mutant huntingtin in Huntington’s disease) are likely the most toxic species4,5. While 
different regions of the brain are affected in these distinct diseases, proteotoxicity is a shared 
feature found in these affected regions of the brain. This suggests that a common mechanism of 
proteotoxicity could contribute to the development and progression of these distinct neurodegen-
erative diseases.  
Proteostasis6,7 is maintained by several systems in the cell including the ubiquitin-proteasome 
system (UPS), chaperones, chaperone-mediated autophagy, and macroautophagy8. The ubiqui-
tin proteasome system (UPS) is the principle route for the degradation of intracellular misfolded, 
damaged, or unneeded proteins9. If the efficiency of proteostasis systems declines, misfolded 
proteins accumulate and aggregate in the cell, which can disrupt normal cellular functions and 
even cause cell death10. Maintaining proteostasis is especially important for neurons due to their 
complex architecture, long lifespan, and inability to dilute aggregate load by cell division11. Most 
importantly, the UPS is critical for normal functioning of neuronal synapses, including synaptic 
protein turnover, plasticity, and long-term memory formation, which rely on tightly controlled 
changes in the proteome11–15. Recently, Ramachandran & Margolis (2017)16 identified a mamma-
lian nervous-system-specific membrane proteasome complex that directly and rapidly modulates 
neuronal function by degrading intracellular proteins into extracellular peptides that stimulate neu-
ronal signaling through postsynaptic N-methyl-D-aspartate receptors.     
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Decreased proteasome function has been reported in a broad array of chronic neurodegenerative 
diseases17. Impaired proteasome function has been implicated, as a primary cause or a second-
ary consequence, in the in the pathogenesis of many neurodegenerative diseases, including Alz-
heimer’s, Parkinson’s, and Huntington’s diseases2,17–21. In fact, brain region-specific proteasome 
inhibition (e.g. forebrain, substantia nigra) closely mirrors the neuropathology and clinical hall-
marks of neurodegenerative diseases22–26. A small percentage of neurodegenerative disease are 
caused by hereditary gene mutations, many of which affect components of the UPS (e.g. PARK1, 
PINK)20. However, the vast majority of neurodegeneration is idiopathic in origin and the involve-
ment of the UPS is less clear17. What is clear in these diseases is that proteins that are normally 
degraded are not properly degraded after misfolding occurs, leading to their accumulation. Sev-
eral groups have provided evidence that aggregated proteins from neurodegenerative diseases 
interact with and impair proteasome function27–37. However, it is not clear what specific types of 
aggregates impair the proteasome, and a mechanistic understanding of how they do so has not 
been elucidated. One study has been able to show that heterogeneous aggregates of the mouse 
prion protein, PrPsc, reduced substrate entry by decreasing proteasomal gating36. Despite these 
many efforts, an understanding of why and how the proteasome is so generally impaired in neu-
rodegenerative disease has remained elusive. Understanding the mechanism of impairment will 
provide a basis for drug development to restore proteasome activity and proteostasis in the brain 
and is therefore an important effort.  
Proteins targeted for proteasomal degradation are marked by the attachment of several ubiquitin 
proteins. These poly-ubiquitinated substrates are recognized by the 26S proteasome and are 
degraded9. The 26S proteasome is made up of a 20S proteasome core particle capped on one 
or both ends by the 19S regulatory particle. It degrades proteins by a multistep process: the 19S 
regulatory particle binds ubiquitinated substrates and opens a substrate entry gate in the 20S38–
40 and unfolds its substrates by translocating them into the 20S catalytic chamber where they are 
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degraded41,42. The 20S is a hollow cylindrical complex composed of four heteroheptameric rings 
arranged in a 7-7-7-7 fashion43. Proteolysis occurs on the interior surface of -subunit rings. 
The substrate gate is formed by the N-termini of the -subunits, which prevent unregulated access 
to the catalytic sites by folding over the entry pore and blocking substrate translocation into the 
catalytic chamber44. Triggering of gate-opening by the 19S requires the C-terminal HbYX motif of 
the 19S ATPases to bind to intersubunit pockets (between the -subunits) on top of the 20S45. 
The HbYX motif allows the 19S to bind to the 20S core particle, but binding of the HbYX motif by 
itself (as a hepta-peptide) is also sufficient to allosterically induce conformational changes in the 
-subunits that cause gate opening45–48. Clearly, regulation of the 20S proteasome gate is an 
important aspect of proteasome function and the cell has evolved many different proteasomal 
regulators that control 20S gate-opening, many of which contain the HbYX motif (e.g. the 19S 
ATPases: Rpt2, Rpt3, Rpt5; Blm10/PA200; Pba1-Pba2; PI31; and archaeal CDC48/P97), and 
some that do not (i.e. the 11S family: PA28 and PA26)48.  
This study demonstrates that misfolded proteins from three distinct neurodegenerative diseases 
adopt a common three-dimensional conformation that is capable of impairing ubiquitin-dependent 
and ubiquitin-independent proteasome function. Although these oligomers possess unique pri-
mary sequences, they all impair the proteasome through allosteric stabilization of the closed gated 
conformation of the 20S core particle, therein blocking protein degradation. Moreover, these toxic 
oligomers specifically impair HbYX motif dependent gate-opening, yet do not impair gate-opening 
induced by the 11S family of regulators. These data suggest that proteasome impairment in var-
ious neurodegenerative diseases may share a common mechanism.  
Results 
Prior studies report conflicting observations regarding the impairment of the proteasome by dis-
ease-related aggregated proteins, some demonstrating proteasome impairment27–30,32–35 while 
others do not49,50. The major limitation of these studies is that the conformational state of the 
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aggregates was not accounted for or considered. Aggregation-prone proteins have the unique 
property of conformational polymorphism. During amyloid formation a variety of aggregate spe-
cies are formed, ranging from small dimers up to large insoluble fibrils. Oligomers are metastable 
intermediates to fibril formation or an off-pathway product of aggregation and are recognized as 
the primary pathogenic effectors51. Since the previous studies used heterogeneous compositions 
of the aggregated proteins, these seemingly conflicting results for proteasome impairment are not 
surprising. In this study, we purify to homogeneity a specific conformation of a pathological oligo-
mer, identified its conformational status, and extensively characterize its mechanism of impair-
ment on human and mammalian 20S/26S proteasomes. In addition, this study identifies a specific 
oligomeric conformation found in Alzheimer’s, Parkinson’s, and Huntington’s disease that sub-
stantially impairs proteasome function in a way that could contribute to the development and pro-
gression of these and other neurodegenerative diseases.  
To determine if specific types of oligomers are responsible for proteasome impairment we began 
by generating various mixed populations of protein aggregates made from either amyloid- 1-42 
(A), -synuclein (-Syn), or huntingtin exon 1 with a polyQ-expansion (Htt-53Q) and asked if 
they could impair purified mammalian 20S proteasome. We found that under specific oligomeri-
zation conditions (different for each protein type) each of the aggregate preparations could signif-
icantly impair the 20S proteasomes ability to hydrolyze fluorogenic peptide substrates (Fig. 1A). 
These results replicate those which have been reported to some extent previously29–31. Next, we 
separated the mixed aggregates into soluble and insoluble fractions and again tested their effect 
on proteasome activity. The soluble oligomers, but not equal amounts of monomers or insoluble 
fibrils, strongly impaired proteasome activity (Fig. 1B) in a concentration-dependent manner (Sup-
plementary Fig. 1). The eukaryotic proteasome has three types of active sites, each displaying 
preference for cleavage after specific residues (chymotrypsin-like, hydrophobic; caspase-like, 
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acidic; trypsin-like, basic). Substrate hydrolysis by all three of the catalytic sites were impaired by 
the soluble oligomers (Supplementary Fig. 2).  
 
Figure 1. A specific conformation of soluble oligomers potently inhibits the mammalian 20S proteasome. (a) Mammalian 
20S proteasomes were incubated with mixed aggregates of A1-42 (5M), -Syn (1M), Htt-53Q (0.1M), or an equal volume of 
oligomer buffer (control). Proteasome activity (linear rate of LLVY-amc   hydrolysis) is represented as a percentage of activity 
compared to the control. (b) Crude aggregates from A were separated into soluble and insoluble aggregates (schematic, left) and 
were assayed as in A (bar graph, right). For huntingtin monomers, Htt-20Q monomers were used because pure Htt-53Q mono-
mers could not be obtained due to rapid oligomerization. Dot blots of monomers, soluble aggregates, and insoluble aggregates 
from B were probed with the conformation-dependent anti-oligomer ‘A11’ antibody (bottom right). (c) Soluble A aggregates from 
B were separated by size exclusion chromatography (SEC) (Abs 280nm, solid blue line). 2l from each fraction was evaluated for 
its effect on 20S proteasome chymotrypsin-like activity (bars) and probed for anti-oligomer A11 reactivity (dot blot, bottom). (d) 
Proteasome activity with up to 5M of A oligomers (A-iO) or A protofibrils (A-PF) from C. (e) Intermediate oligomers from D 
were pre-incubated with anti-oligomer A11 antibody (A-iO + A11) or an equal volume of antibody buffer (A-iO) for 30 minutes 
at 37°C before to addition to proteasome activity assay. Final concentration of A-iO in the assay was 0.25M (the ~IC50 as 
determined in D). The concentrations of aggregates are calculated based on the respective monomeric peptide/protein mass (A, 
4.5 kDa; -Syn, 14 kDa; and Htt-53Q, 22 kDa). All controls contained an equal volume of buffer identical to that of the respective 
aggregates. Data are representative of three or more independent experiments performed in triplicate. Error bars represent ± 

















Supplemental Figure 1. Corresponds to Figure 1B.  
A11(+) soluble aggregates of A, -Syn, and Htt-53Q impair the 
mammalian 20S proteasome in a concentration-dependent 
manner. Mammalian 20S proteasomes were incubated with solu-
ble aggregates of A (a), -Syn (b), or Htt-53Q (c) at the indicated 
concentrations and proteasome activity (LLVY-amc hydrolysis) was 
measured. A mixed aggregates are the same as used in Figure 
1a. Soluble oligomers from -Syn and Htt-53Q are from Figure 1b. 
Half-maximal inhibition of the 20S is indicated. The concentrations 
of aggregates are calculated based on the respective monomeric 
peptide/protein mass (A, 4.5 kDa; -Syn, 14 kDa; and Htt-53Q, 22 
kDa). All controls contained an equal volume of buffer identical to 
that of the respective aggregates. Data is representative of three 
independent experiments performed in triplicate. Error bars repre-
sent ± standard deviation. Sigmoidal dose response (variable slope) 
line fit performed with GraphPad version 7. 
Htt-53Q Htt-53Q Htt-53Q 
Supplemental Figure 2. Corresponds to Figure 
1B.  
A11(+) oligomers from A, -Syn, and Htt-53Q 
impair substrates that are specific for all three 
proteolytic sites in the mammalian 20S pro-
teasome. Mammalian 20S proteasomes were in-
cubated with A oligomers (2M) (a), -Syn A11+ 
oligomers (1M) (b), or Htt-53Q A11+ oligomers 
(0.1M) (c), and proteasome chymotrypsin-like 
(LLVY-amc hydrolysis), caspase-like (nLPnLD-
amc hydrolysis), and trypsin-like (RLR-amc hydrol-
ysis) activity was measured. Chymotrypsin-like and 
caspase-like activity assays used 0.5nM of 20S 
proteasome, trypsin-like activity assays used 1nM 
of 20S proteasome. The concentrations of aggre-
gates are calculated based on the respective mon-
omeric peptide/protein mass (A, 4.5 kDa; -Syn, 
14 kDa; and Htt-53Q, 22 kDa). All controls con-
tained an equal volume of buffer identical to that of 
the respective aggregates. Data is representative 
of three independent experiments performed in 
triplicate. Error bars represent ± standard devia-
tion. ****p<0.0001; ***p<0.001; **p<0.01 (students 
















A, -Syn, and Htt-53Q monomers are relatively unstructured and they can enter the 20S pro-
teasome to be degraded. However, the monomers fail to impair peptide hydrolysis by the pro-
teasome at equal concentrations as the oligomers (Fig. 1B) therefore, substrate competition at 
the active site cannot explain impairment by the oligomers. Furthermore, oligomers are too large 
(Fig. 2G-H) to enter the 13Å wide substrate-entry channel of the 20S proteasome. Additionally, 
since the insoluble aggregates of these proteins cannot impair the proteasome (Fig. 1B), this 
suggests that impairment by the oligomers may be due to a specific conformation of the soluble 
oligomers which is lost after conversion to larger aggregates or fibrils. This is consistent with 
literature that ascribes cellular toxicity to soluble oligomers in neurodegenerative diseases4,52,53. 
Many species of oligomeric structures have been described, and antibodies developed to recog-
nize specific structural conformations of disease related species54–56. Kayed et al. (2003)55 gen-
erated a polyclonal anti-oligomer antibody (A11) that specifically recognizes some types of protein 
oligomers independent of the proteins amino acid sequence. This A11 antibody recognizes some 
oligomeric species of A, polyglutamine proteins, -synuclein, and prion, and has been used to 
assess the presence of oligomers in diseased brains compared to aged matched controls55,57. We 
performed a dot blot with A11 on the monomers, oligomers, and insoluble fibrils for each protein 
that we tested. All three of the soluble oligomer preparations contained the A11 epitope (A11+), 
while the epitope was absent in the monomeric and fibril fractions (Fig. 1B bottom). 
It is interesting that all three soluble oligomer types that impaired proteasome activity also showed 
strong A11 antibody binding. To correlate proteasome impairment with the presence of the A11 
epitope more specifically, the soluble fraction of the A aggregates were separated by size exclu-
sion chromatography. Three prominent populations of soluble aggregates were observed, one in 
the void volume consistent with larger protofibrils (A-PF), a second peak corresponding to inter-
mediate sized oligomers (A-iO) and a third pool of small oligomers and monomers (Fig. 1C-
chromatogram). The effect of each fraction on 20S proteasome activity was determined. Only the 
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intermediate sized oligomers (~56kDa) impaired the 20S proteasome (Fig. 1C bars) and this im-
pairment correlated with the fractions that were positive for A11 (Fig. 1C dot blot). This inhibitory 
species also impaired the degradation of fluorogenic substrates specific for each of the 20S’s 
three different proteolytic sites as observed in the mixed oligomer populations (Supplementary 
Fig. 3A). This suggests that impairment could be due to impairment of substrate entry rather than 
impairment of a specific catalytic active site. The A protofibril peak (A-PF), lacking the A11 
epitope, did not impair degradation of any fluorogenic substrates, even in the presence of ten 
times more A protofibrils than A intermediate oligomers (Fig. 1D & Supplementary Fig. 3B).  
Supplemental Figure 3. Corresponds to 
Figure 1C.  
A11(+) A intermediate oligomers (A-iO) 
impair the degradation of substrates spe-
cific for each of the three peptidase activ-
ities in the 20S, and A11(-) A protofibrils 
(A-PF) do not have any effect. Mamma-
lian 20S proteasomes were incubated with 
peak A fractions from size exclusion chro-
matography in Fig. 1D:  2.5M A-iO (a) or 
5M A-PF (b). Chymotrypsin-like (LLVY-
amc hydrolysis, rfu/min) and caspase-like 
(nLPnLD-amc hydrolysis, rfu/min) activity 
assays used 0.5nM of 20S proteasome, tryp-
sin-like (RLR-amc hydrolysis, rfu/min) activ-
ity assays used 2nM of 20S proteasome. 
The concentrations of aggregates are calcu-
lated based on the monomeric peptide mass 
(4.5 kDa). All controls contained an equal 
volume of buffer identical to that of the re-
spective aggregates. Data is representative 
of three independent experiments performed 
in triplicate. Error bars represent ± standard 






Supplemental Figure 4. Corresponds to Figure 1C. 
Soluble high molecular weight A oligomers also impair the 20S proteasome if they are A11 positive. (a) High molecular 
weight A11(+) oligomers of A were separated by size exclusion chromatography, peak fractions (10l) were separated by native-
PAGE and coomassie stained (top). Each fraction (2l) was evaluated by slot blot for A11 immunoreactivity (bottom). (b) 20S 
proteasome activity (nLPnLD-amc hydrolysis, rfu/min) was determined with fractions from part A (0.5l). The concentrations of 
aggregates are calculated based on the monomeric peptide mass (4.5 kDa). All controls contained an equal volume of buffer 
identical to that of the respective aggregates. Data is representative of three independent experiments performed in triplicate. 
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It is plausible that proteasome impairment is due to the oligomer size rather than a specific oligo-
meric structure. To determine if the impairment is due to the size of the oligomer/protofibrils and 
whether the shared A11 reactivity is merely a coincidence, we generated high molecular weight 
(200-400 kDa) A11+ A oligomers (Supplementary Fig. 4A) and A11+ A-protofibrils (>700 kDa) 
(Supplementary Fig. 5A). The high MW A11+ A oligomers impaired the 20S commensurate with 
the level of A11 reactivity (Supplementary Fig. 4A & B). The higher molecular weight A11+ A 
protofibrils also impaired substrate hydrolysis by all three active sites of the proteasome (Supple-
mentary Fig. 5B), although to a considerably lesser extent than the intermediate A oligomers 
(Fig. 1D). This is expected because protofibrils form when oligomers bind to one another to form 
a chain of oligomers58, which sterically blocks surfaces on the internal oligomers but not the ter-
minal ones, which could still interact with the proteasome. To further determine if the structural 
epitope of the A11 antibody on the intermediate A oligomers is necessary for proteasome im-
pairment we performed a neutralization assay to block the A11 epitope. A11+ oligomers were 
incubated with the A11 antibody prior to testing proteasome activity. A oligomers were used at 
a concentration of 0.2M, the IC50, as determined in Fig. 1D, so an increase or decrease in pro-
Supplementary Figure 5. Corresponds to Figure 1C.  
A11(+) A protofibrils impair the mammalian 20S proteasome. (a) A11(+) A protofibril preparation was separated by size 
exclusion chromatography (Superose 6 GL). The protofibrils eluted in the column void volume, indicating the soluble aggregates 
are >700 kDa (top). Equal volumes of each fraction were probed for A11 reactivity (bottom). (b) Mammalian proteasomes were 
incubated with A11(+) A protofibrils (2.5M) and the activity of all three active sites was measured by fluorescent substrate 
hydrolysis. The concentrations of aggregates are calculated based on the monomeric peptide mass (4.5 kDa). All controls con-
tained an equal volume of buffer identical to that of the respective aggregates. Data is representative of three independent exper-





teasome activity could be readily observed. Indeed, the A11 antibody when bound to the A oli-
gomers completely rescued proteasome activity (Fig. 1E). As a control, the experiment was re-
peated with an antibody raised against the N-terminal residues of A (clone NAB228), which did 
not rescue proteasome function (Supplementary Fig. 6). This demonstrates that an available oli-
gomer-specific A11 epitope site is necessary for impairment of the proteasome.  
Generation and characterization of homogenous and stable A11+ A*56 oligomers 
Above we described the isolation of a specific proteasomal inhibitory oligomer from a mixed pop-
ulation of oligomers and aggregates. In order to determine the mechanism of impairment we 
sought to generate homogenous, stable, and reproducible A11+ oligomers, which could be used 
for reliable mechanistic analysis. In contrast to -synuclein and huntingtin aggregates, methods 
to generate physiological relevant oligomers from synthetic A peptides have been extensively 
developed. Barghorn et al. (2005)59 characterized a highly stable A (1-42) oligomer species 
(~dodecamer) which can be prepared in vitro and can be found in the brains of patients with AD. 
The relevance of dodecameric A oligomers to disease pathology is established57,60. With some 
modifications to the protocol of Barghorn et al., 2005 we generated A*56 oligomers, and purified 
them by nondenaturing size exclusion chromatography (Fig. 2A chromatogram). The major peak 
corresponds to the intermediate sized A oligomers in Figure 1D. We tested each fraction for 
proteasome activity and found the major peak impaired the 20S (Fig. 2A bar graph). The single 
symmetric protein peak demonstrates the homogenous nature of the oligomer preparations. Con-
sistent with A*56 oligomers isolated from human brain tissue and cerebrospinal fluid, our A*56 
Supplementary Figure 6. Corresponds to Figure 1E. 
Incubation with antibody targeted to the A N-terminus (1-8) does not rescue pro-
teasome activity. A intermediate oligomers (A-iO) from Fig. 1D were incubated with 
buffer or monoclonal antibody (NAB228, Invitrogen, epitope 1-8 A peptide) for 30 
minutes at 37oC and tested for effect on proteasome activity (nLPnLD-amc hydrolysis). 
The concentration of oligomers is calculated based on the monomeric peptide mass 
(4.5 kDa). Controls contained an equal volume of buffer identical to that of the A oli-
gomers and/or the NAB228 antibody. Data is representative of three independent ex-
periments performed in triplicate. Error bars represent ± standard deviation. 





oligomers are A11+ (Fig. 2A), run at ~56 kDa (Fig. 2B)57, and significantly impair proteasome 
activity in a concentration dependent manner (Fig. 2C). Representative real-time fluorogenic sub-
strate hydrolysis data is also shown (Fig 2D).  
Figure 2. Generation of stabilized A11+ oligomers (A*56) for mechanistic evaluation of proteasome inhibition. (a) Size 
exclusion chromatography (Superose 6 GL 10/300) run that was used to generate a pure A*56 oligomer preparation (blue solid 
line, left axis), with proteasome activity (amc hydrolysis) from 1l of the corresponding fractions (bars, right axis; as in Fig. 1), and 
A11 dot blot (bottom panel). (b) Native-PAGE A*56 peak fraction from “A” followed by western blot using the A11 anti-oligomer 
antibody. (c) Proteasome activity (LLVY-amc hydrolysis) with titrating A*56; the IC
50
 is approx. 0.22M A (4.5 kDa monomeric 
mass) or 18 nM A*56 oligomer complexes (56 kDa mass each). (d) Representative raw data of proteasome activity assay 
(nLPnLD-amc hydrolysis) with 1.5M A*56 oligomers (data point from C). (e) Change in polarization of FITC labeled-casein 
protein (due to cleavage) in the presence of the 20S proteasome, with and without 10M A*56. (f) Rate of FITC-casein degra-
dation (mP/min). (g) Representative negative stain electron microscopy image of purified A*56 oligomers. Scale bar is 25nm. 
(h) Representative tapping mode atomic force microscopy topography image of A*56 oligomers. Scale bar is 0.5m. Heat map 
for oligomer height is shown on the right. (i) ThT fluorescence of the indicated A preparations. (j-k) Dot blot with A11 antibody 
(j) and oligomer native gel electrophoresis visualized by coomassie stain (k) of non-crosslinked and glutaraldehyde crosslinked 
(CL) A*56 oligomers before and after 4-week incubation at 4°C. (l) Proteasome activity (nLPnLD-amc hydrolysis) in the presence 
of crosslinked and non-crosslinked A*56 oligomers (0.75M). Concentration of A*56 oligomers is calculated based on the mass 
of peptide monomer (A, 4.5 kDa). All controls contained an equal volume of buffer identical to that of the respective aggregates. 
Proteasome activity was calculated as in Fig 1A. Data is representative of three or more independent experiments performed in 
triplicate. Error bars represent ± standard deviation. All following experiments utilize crosslinked A*56 oligomers unless indicated 






Since A*56 can impair 20S peptide substrate degradation, we asked if it could impair protein 
degradation as well. The 20S core particle by itself cannot unfold proteins, so we used -casein, 
a classical unfolded protein substrate. We used FITC-labeled casein to follow its degradation in 
real time using anisotropy, which monitors the tumbling rate of the fluorophore. When FITC-la-
beled casein is degraded by the proteasome, the tumbling rate of the fluorophore increases, caus-
ing a decrease in anisotropy (Fig. 2E 20S+buffer). Similar to peptide substrates, purified A*56 
oligomers also impaired proteasome degradation of the FITC-labeled casein protein (Fig. 2E 
20S+A*56), demonstrating that A*56 also impairs the degradation of an unfolded protein. We 
confirmed that the relevant morphology of these oligomers were consistent with those published 
for synthetic and human brain derived oligomers via: native gel electrophoresis57,61 (for MW), 
TEM62 (for spherical shape), AFM63,64 (for size), Thioflavin-T staining65 (slight but low staining), 
and anti-oligomer immuno-detection57,65 (Fig. 2G-I).  
Oligomers are metastable intermediate structures which complicates analysis when consistent 
homogeneous preparations are needed for in depth biochemical analysis. To circumvent this is-
sue, we stabilized the A*56 oligomers by crosslinking, which maintained the conformation of the 
A11+ epitope for four weeks when stored at 4oC (Fig. 2J) and without crosslinking the A11+ 
epitope was not as stable over this time period.  In addition, the apparent mass of the crosslinked 
oligomers was also assessed via Native-PAGE and we found that it was unchanged over the four-
week incubation (Fig. 2K). The crosslinked A*56 oligomers ran slightly faster than the non-cross-
linked oligomers as expected59, likely due to stabilization of the crosslinked structure. In contrast, 
the non-crosslinked oligomers partially dissociated into smaller oligomers and formed larger oli-
gomers after four weeks (Fig. 2K). Most importantly, crosslinking of the oligomers does not alter 
their proteasome impairment activity compared to the non-crosslinked form (Fig. 2L). Together, 
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this demonstrates that the synthetic A*56 oligomers are homogenous, relevant, stable, repro-
ducible, and represent a single oligomeric species that potently impairs peptide and protein deg-
Figure 3. The A11(+) oligomers bind to the 20S proteasome and impair opening of the substrate gate. (a) 20S proteasomes 
(0.4g) and pure non-crosslinked A*56 oligomers (1.5g) were incubated separately or together for 30 minutes (37℃), crosslinked 
with 1mM glutaraldehyde for 5 minutes, and separated by Native-PAGE (4-8% tris-acetate gel). Total protein was detected by silver 
stain (left), and total A was detected by western blot (right). (b-d) The activity of yeast 20S wild-type (WT) and open-gate (3N) 
proteasomes was measured for all three proteolytic sites in the presence of A11(+) oligomers from A*56 (B; 2.5M), -Syn (C; 
100nM), and Htt-53Q (D; 50nM). Chymotrypsin-like activity was measured by LLVY-amc hydrolysis, trypsin-like activity by RLR-
amc, and caspase-like by nLPnLD-amc hydrolysis. The concentrations of aggregates are calculated based on the respective mon-
omeric peptide/protein mass. All controls contained an equal volume of buffer identical to that of the respective aggregates. Data is 
representative of three or more independent experiments performed in triplicate. Error bars represent ± standard deviation. 
****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns p>0.05 (students t test). 
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radation by the 20S proteasome. These crosslinked A*56 oligomers are therefore ideally suited 
for further mechanistic and biochemical analysis to understand how oligomers impair proteasome 
function and are thus used in all of the following experiments using A oligomers unless stated 
otherwise.  
Direct binding of A*56 to 20S proteasome 
We next sought to determine if A*56 and the 20S proteasome could be observed to directly 
interact. Non-crosslinked A*56 oligomers were mixed with purified 20S proteasomes. To stabi-
lize their interaction, we used a low concentration of glutaraldehyde (1mM) to induce crosslinking 
and analyzed migration. A*56 is clearly seen co-migrating with the 20S proteasome by Native-
PAGE gel visualized with both silver stain (Fig. 3A left) and by immunoblotting for total A (Fig. 
3A right). Notably, the low concentration of glutaraldehyde treatment did not cause random non-
specific protein crosslinking and did not crosslink the entire multisubunit proteasome into a single 
700 kDa complex as determined by the absence of protein aggregates in the SDS-PAGE stacking 
gel (Supplementary Fig. 7). Minimal crosslinking conditions are further demonstrated by the dis-
crete banding pattern of multiple subunits and the persistence of two single subunit bands (Sup-
plementary Fig. 7). 
Toxic oligomers impair proteasome gate  
Substrates must pass through the gated trans-
location channel before gaining access to the 
proteolytic sites44. The A11+ oligomers are too 
large to enter the 13Å translocation channel 
and directly inhibit -subunit active sites; how-
ever, they could be impairing 20S proteasome 
function by impairing substrate entry through 
Supplementary Figure 7. Corre-
sponds to Figure 3A. 
A*56 oligomers bind to the 20S 
proteasome. (A) 20S proteasomes 
(0.4g) and A*56 oligomers (1.5g) 
(from Figure 3A) were incubated sep-
arately or together for 30 minutes 
(37oC), were lightly crosslinked for 
5min, and then separated by SDS-
PAGE (4-12% bis-tris gel). Total pro-
tein was detected by silver stain. 
Lane 2 shows 20S proteasome mi-
gration pattern without crosslinking 
for comparison. Lane 3 brackets de-
note intra-proteasome crosslinked 
subunits after glutaraldehyde treat-
ment (top bracket) and individual 
subunits that did not crosslink (bot-
tom bracket). The lack of aggregated 
protein in the stacking gel (*) indicat-
ing minimal crosslinking conditions. 
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the gate or by allosterically impairing the active sites. To address this question, we used the 3N 
proteasome mutant, which has a constitutively open gate66. If the oligomers impair proteasome 
activity by clogging the catalytic chamber or allosterically impairing the active sites, then they 
should be able to impair the proteasome regardless if its substrate-gate is in the opened or closed 
state. Alternatively, if the oligomers require a functioning gate for impairment, then they should 
not be able to impair a proteasome with a constitutively open gate, i.e. the 3N 20S proteasome, 
which lacks only 1 of its 7 -subunit N-termini44.  We added the three different A11+ oligomers: 
A*56, -Syn, and Htt-53Q, to the WT or the 3N 20S proteasome and monitored substrate 
degradation. All three A11+ oligomers significantly impair wild-type proteasomes but do not impair 
the 3N proteasomes (Fig. 3B-D). These results demonstrate that the A11+ oligomers require 
a functioning gate in order to impair the 20S proteasome. In addition, most active site proteasome 
inhibitors only inhibit one or two proteolytic sites, but the A11+ oligomers impair the degradation 
of substrates specific for each of the three different catalytic sites (Fig. 3B-D), further supporting 
a gating mechanism of impairment, since restricting substrate access would be expected to impair 
all types of substrates. Moreover, a translocation channel clogging mechanism can also be ruled 
out since the 3N 20S proteasome could not be impaired. To further confirm an allosteric mech-
anism of proteasome impairment, we performed a substrate saturation curve on the WT 20S 
proteasome with and without A*56 oligomers. We used non-linear regression and the Michaelis-
Menten equation to analyze the KD and Vmax of the two curves. We found that the A*56 oligomers 
caused a decrease in the Vmax (49.51 to 26.48 µM substrate) and an increase in the Km (9.816 to 
18.57 µM substrate) (Supplementary Fig. 8), which is consistent with allosteric inhibition (i.e. 
mixed inhibition—a form of noncompetitive inhibition). Taken together, these data clearly demon-
strate that all three diseases-related oligomers impair proteasome function by a similar allosteric 
mechanism, since all three A11+ oligomers require a closable gate on the 20S proteasome in 
order to impair it. 
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 To validate the preparation of the open-gate 3N 20S proteasomes, they were incubated with 
either a known gate-opening peptide (KANLQYYA45 from the C-terminus of Rpt5, which includes 
the HbYX motif) or the -subunit active site inhibitor, MG132. Treatment with MG132 completely 
inhibits WT and open-gate 3N proteasomes (Supplementary Fig. 9A) as expected for a pure 
proteasome preparation. The Rpt5 peptide increases WT 20S proteasome substrate degradation 
but failed to stimulate the open-gate 3N 20S proteasome (Supplementary Fig. 9B) as expected 
for proteasomes with constitutively open gates. The preparations of pure 3N 20S were approx-
imately 10 times more active than the WT 20S and thus ten times more WT 20S was used in 
these experiments to obtain comparable basal rates (Supplementary Fig. 9).  
  
 
Supplementary Figure 8. Corresponds to Figure 3. 
Substrate saturation curve on the WT 20S pro-
teasome with and without A*56 oligomers. Mam-
malian 20S proteasomes (0.5nM) were assayed for 
nLPnLD-amc hydrolysis activity with and without 
A*56 oligomers (1.2M) for 60 minutes at various 
substrate concentrations. The rate of amc- hydrolysis 
was plotted and line fit using non-linear regression 
and the Michaelis-Menten equation (GraphPad ver-
sion 7). Vmax and Km values are shown to the right. 























Supplemental Figure 9. Corresponds to Figure 3B-D. 
WT and a3ΔN proteasome preparations have expected activities. (a) Chymotrypsin-like activity (LLVY-amc hydrolysis) is 
abolished in both wild-type 20S and 3N 20S mutant proteasomes after pre-treatment with proteasome inhibitor MG132 (50M). 
(b) Wild type 20S proteasomes (1.4 nM) show gate opening by addition of a known gate-opening peptide, Rpt 5 (300M). How-
ever, as expected the Rpt5 peptide could not stimulate the open-gate mutant 3N 20S proteasomes (0.14 nM). Note there is 
10X more WT 20S than 3N 20S. Data is representative of three independent experiments performed in triplicate. Error bars 








Toxic oligomers stabilize the proteasomes closed gate conformation 
Binding of the 19S ATPases C-termini HbYX motif into the 20S intersubunit pockets induces a 
conformational change of the 20S -subunits, which stabilizes the open state of the N-terminal 
gating residues9,45. However, recent cryo-EM studies have highlighted the complexity of this gate-
opening mechanism in the 26S proteasome when the 19S binds to a substrate (or when it is 
switched from an ATP-bound state to an ATPS bound state)67,68. It is less clear how the dynamics 
Figure 4. A11(+) oligomers cannot inhibit PA26 or PA28 induced gate opening. (a-c) 20S Proteasome activity with and 
without the proteasome activator PA26 (1g/100l) was determined in the presence of A11(+) oligomers from A*56 (1.5M, A), 
-Syn (0.1M, B), or Htt-53Q (0.1M, C). Broken graphs are used to show the extent of 20S inhibition while still showing the 
extent of PA26 activation. (d) Proteasome activity in the presence of increasing concentrations of PA26 with and without A11(+) 
A*56 (1.5M). The sigmoidal equation was fit to the averages from three independent experiments (normalized to % activity) 
performed in triplicate, error bars ± S.E.M. For A, B, C, & D, the 20S proteasome activity (nLPnLD-amc hydrolysis, rfu/min) was 
normalized to 20S control activity without activator. (e) Proteasome activity with PA26 activator (1g/100l) in the presence of 
increasing concentrations of A*56 (left). Activity of 20S proteasome (without PA26) with 1.5M A*56 is shown at right. (f) Same 
experiment as in A, with human PA28 replacing PA26. The concentrations of oligomers are calculated based on the respective 
monomeric peptide/protein mass. All controls contained an equal volume of buffer identical to that of the respective aggregates. 
Data is representative of three or more independent experiments performed in triplicate. Error bars represent ± standard deviation. 













of the gate changes when the 19S associates with the 20S. Nevertheless, functional studies have 
shown that 19S binding to the 20S stimulates gate-opening in the 20S proteasome39,40, in a HbYX 
motif dependent manner47. In contrast, the 11S family of proteasome activators (e.g. PA28 
and PA26) bind to the 20S -subunits and facilitate gate opening by a different mechanism. Alt-
hough the 11S subunits also bind to the -intersubunit pockets, they lack the HbYX motif and 
thus do not induce -subunit conformational changes like the HbYX motif does. Instead, the 11S 
internal “activation loop” is required for gate opening. This “activation loop” directly contacts the 
base of the N-terminal gating residues and locally repositions them into the open conformation69. 
We hypothesized that binding of the A11+ oligomers to the 20S may specifically impair one of 
these distinct gate-opening mechanisms, which would provide evidence for the mechanism of 
oligomer-mediated proteasome impairment. If the oligomers could impair the PA26-20S complex, 
then it is expected that they would bind to the top of the 20S and compete with PA26 for binding 
to the 20S. Alternatively, if the oligomers do not compete with PA26 for binding to the 20S but 
they do impair the HbYX dependent gate-opening this indicates that oligomers must allosterically 
affect conformational changes that are caused upon HbYX motif binding. Another possibility is 
that the oligomers affect both or neither mechanisms of gate-opening. To assure that both ends 
of the 20S proteasome were bound by PA26 we used saturating amounts to stimulate 20S peptide 
degradation. None of the A11+ oligomers from A, -Syn, or Htt-53Q could impair the PA26-20S-
PA26 complex (Fig. 4A-C). Thus, the PA26-20S-PA26 complex mirrors the results obtained for 
the 3N-20S. To evaluate this possibility that the oligomers compete with PA26 for binding to 
the 20S we generated a binding saturation curve for PA26 to 20S by monitoring 20S proteasome 
activation in the presence and absence of A11+ A*56 oligomers. The apparent affinity of PA26 
binding for the 20S did not decrease in the presence of the A11+ oligomers (Fig. 4D), and the 
oligomers did not impair PA26 at any concentration that was used, indicating that the oligomers 
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do not compete with PA26 for binding to the 20S. Additionally, the A*56 oligomers could not 
impair PA26 mediated gate opening even at very high A*56 concentrations (Fig. 4E).  
Figure 5. A*56 oligomers inhibit ubiquitin-dependent and ubiquitin-independent degradation of full-length proteins. (a-
d) Purified human 26S proteasomes. (a) Human 26S proteasome activity (LLVY-amc hydrolysis, rfu/min) with 2M A*56 com-
pared to buffer control. (b) Change in fluorescence of polyubiquitin-GFP fusion protein (Ub4(lin)-GFP-35) in the presence purified 
human 26S proteasome, with and without 5M A*56. (c) Rate of polyubiquitin-GFP fusion protein (Ub4(lin)-GFP-35) degradation 
in C (rfu/min). (d) Purified human 26S proteasomes were incubated with or without A*56 for 90 minutes at 37°C, and separated 
by Native-PAGE and silver stained. Band density was quantified with ImageJ. Band density is shown as a percentage of total 
density of each lane. (e-h) Full length protein degradation in mouse brain lysates. (e) Change in polarization of FITC labeled-
casein in 2g mouse brain lysates, with and without 10M A*56. (f Rate of FITC-casein degradation in E (mP/min). (g) Change 
in fluorescence of polyubiquitin-GFP fusion protein (Ub4(lin)-GFP-35) in 2g mouse brain lysates, with and without 10M A*56. 
(h) Rate of polyubiquitin-GFP fusion protein (Ub4(lin)-GFP-35) degradation in G (rfu/min). The concentration of A*56 oligomers 
is calculated based on Aβ monomeric peptide mass (4.5 kDa). All controls contained an equal volume of buffer identical to that of 
the A*56 oligomers. Data is representative of three or more independent experiments performed in triplicate. Error bars represent 










The PA28 proteasome activator from humans is a homologue of PA26 and thought to open the 
20S gate in a similar activation loop-dependent manner69. Consistent with PA26 results, the A11+ 
A*56 oligomers could not impair the human PA28 mediated proteasome gate opening (Fig. 
4F). Therefore, the A11+ oligomers bind to the 20S proteasome at a location separate from the 
11S proteasome activators, PA26 and PA28. Based on this we hypothesized that the oligomers 
stabilize the latent closed conformation of the -subunits which is not affected by the PA26/28 
activation loop-dependent gate opening. To test this hypothesis, we asked if the A11+ oligomers 
could impair peptide and protein degradation by purified human 26S proteasomes. The A11+ 
A*56 oligomers significantly impaired peptide degradation by the purified 26S proteasome com-
pared to controls (Fig. 5A).  
To further test this possibility, we determined if oligomers could impair ubiquitin dependent 
(Ub4(lin)-GFP-35) protein degradation by purified human 26S proteasomes. The Ub4(lin)-GFP-35 
substrate we used to monitor ubiquitin dependent degradation is a circularly permuted GFP with 
a linear tetra ubiquitin on N-terminus and a 35-residue unstructured region on the C-terminus that 
was created in the Matousheck lab. We found that A*56 also strongly impaired the degradation 
of this structured protein (Fig. 5B-C) by the human 26S proteasome, which requires ATP-depend-
ent unfolding and injection into the 20S core. These data suggest the oligomers impair the HbYX 
mechanism of gate opening. However, it is possible that the oligomer binding to the 20S could 
cause the 26S to disassemble into its 20S and 19S subcomplexes, which could also have the 
effect of impairing the ubiquitin-dependent protein degradation that we observed. To test this pos-
sibility, we incubated A*56 oligomers and purified human 26S proteasome preparations together 
for 90 minutes at 37C before running the samples on native-PAGE (Fig. 5D). We quantified the 
silver stain band densities for isolated 20S, singly capped 26S, and doubly capped 26S. The 
relative ratio of these three populations of proteasomes did not change with the incubation with 
A compared to control. 
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The prior experiments where done with highly purified components thus providing good cause 
and effect confidence for mechanistic analysis; however, the purified system cannot assess if the 
oligomers are able to bind to and impair the proteasome in an environment that more closely 
mimics a complex cellular environment. To address this, we prepared mouse brain lysates to 
determine if the toxic oligomers could still impair protein degradation by the proteasome in such 
a heterogeneous environment. We found that the brain lysates were highly competent to degrade 
the protein substrates FITC-casein (Fig. 5E-F) and Ub4 (lin)-GFP-35 proteins (Fig. 5G-H) similar 
to the purified 26S proteasome (Fig. 5B-C). We also assessed the proteasome activity compo-
nent of this lysate by adding the proteasome inhibitor MG132, and found that the majority of the 
degradation activity we observed was due to proteasome activity (Fig. 5E-H).  
When we assessed the degradation of these two specific proteins in brain lysates, in the presence 
of the crosslink-stabilized A*56 we observed extensive proteasome impairment—nearly as much 
as when MG132 was used (Fig. 5E-H). Therefore, the A11+ A*56 oligomers retain enough 
specificity to bind to and nearly completely impair proteasome function even in a complex brain 
lysate. These data demonstrate that the oligomers do not disrupt the 26S complexes, and thus 
do not impair it by this mechanism, but must instead act, as we expected, on the gate. Impairment 
of the 26S proteasome also demonstrates that the oligomers must bind to the 20S even in the 
presence of the 19S, as was also observed for the PA26-20S complexes, demonstrating that the 
oligomers likely bind to the outer surface of the 20S proteasome (i.e. not on the gating surface) 
thus supporting the hypothesis that these toxic oligomers act allosterically preventing the 20S 
gate from opening properly. Since these results clearly demonstrate that A11+ oligomers are able 
to impair the 20S core particle by itself, then it’s most likely that their impairment of the 26S pro-
teasome is via the same mechanism, acting on the core particle. Importantly, this result demon-




The 19S requires binding of ATP for it to bind to and induce gate opening in the 20S73. The 26S 
proteasome adopts multiple conformations during the ATP hydrolysis cycle and substrate degra-
dation67,74–76. In the presence of hydrolysable ATP, 26S proteasomes seems to alternate between 
active (open gate) and inactive (closed gate) states, with the inactive state predominating, and in 
contrast, non-hydrolyzing ATP analogues better stabilize the active (open gate) form of the pro-
teasome67,77. Interestingly, while the A*56 oligomers impaired the 26S in the presence of ATP, 
they could not impair the 26S in the presence of the analog ATPS (Fig. 6A). This shows that the 
oligomers are able to impair the normal physiological (with ATP) state of the 26S but not the 
Figure 6. HbYX-dependent 20S gate opening counteracts inhibition by A*56 oligomers.  
(a) Mammalian 26S proteasome activity (LLVY-amc hydrolysis, rfu/min) with 2mM ATP or 10M ATPS. A*56 titration up to 
6M. (b) 20S proteasome activity (nLPnLD-amc hydrolysis, rfu/min) with RPT5 peptide titration, with and without A*56 (0.5M). 
(c) Schematic depicting our working model for proteasome inhibition by A11(+) oligomers (see text for details). The concentra-
tion of A*56 oligomers is calculated based on A monomeric peptide mass (4.5 kDa). All controls contained an equal volume 
of buffer identical to that of the A*56 oligomers. Data is representative of three or more independent experiments performed in 




synthetically opened state (using ATPS), in 
which the open state is more “strongly” stabi-
lized. We verified the integrity of the purified 
26S proteasomes preparation via Native-
PAGE to confirm that the observed activity 
came only from the 26S complexes (Supple-
mentary Fig. 10) and not from any free 20S proteasome in the preparation. These results thus 
further support the hypothesis that these oligomers oppose the HbYX-dependent conformational 
changes that lead to gate-opening.  
To further test this hypothesis, we asked if the A11+ oligomers could block HbYX-dependent gate 
opening directly by the Rpt5 peptide (KANLQYYA), an established gate opening peptide45, de-
rived from the C-terminus of Rpt5. We added increasing concentrations of the Rpt5 peptide to the 
20S proteasome with and without the A11+ A*56 oligomers. In the absence of oligomers, the 
Rpt5 peptide significantly stimulated proteasome activity as expected. However, the oligomers 
impaired Rpt5 activation at all concentrations. Interestingly, the more Rpt5 was added the less 
effective the oligomers were to impair the proteasome (Fig. 6B). These results indicate that the 
oligomers impair HbYX dependent gate opening, but also that HbYX peptide could overcome 
impairment by the oligomers at the higher concentrations (1mM Rpt5 peptide was the highest 
concentration that could be tested due to its solubility). In contrast, the oligomers could not impair 
PA26 activation at any concentration of PA26. We interpret these results to mimic the ATP/ATYS 
experiment (Fig. 6A) whereby the ATP state is a low HbYX occupancy state and the ATPS state 
is a higher occupancy HbYX state. The rational is that ATP is rapidly hydrolyzed to ADP, and ADP 
cannot support HbYX-dependent gate-opening. On the other hand, ATPS is not hydrolyzed to 
ADP and thus it sustains the HbYX bound open-gate state or it could also enhance gate-opening 
by other mechanisms77. These combined results fit well with a model whereby the A11+ oligomers 
Supplemental Figure 10. Cor-
responds to Figure 6A. 
The measured amc hydrolysis 
from 26S proteasome prepara-
tion is due to single and dou-
ble capped 26S activity and 
not 20S activity. Native-PAGE 
of 1g of mammalian rabbit mus-
cle 26S proteasome. In-gel en-
zyme activity assay (LLVY-amc 
hydrolysis) (left), silver stain 
(right). Gel is representative of 
three 26S proteasome prepara-
tions from rabbit muscle. Note 
that the LLVY-amc activity is only 
detectable from the 20S-19S 




impair proteasome function by binding to the outer surface of the 20S barrel, and impair substrate 
entry by allosterically stabilizing the closed conformational state of the 20S -subunits, in a way 
that directly counteracts the conformational changes that are required for HbYX-dependent gate-
opening. 
Discussion 
The structural evolution of compartmentalized proteases was driven by the need to protect prote-
olytic activity from the cellular milieu, but still have the capacity to degrade select proteins in a 
regulated manner. The substrate-entry gate in the 20S proteasome thus plays a critical role in 
proteasome function and in cellular proteostasis. Here, we elucidate a common mechanism 
whereby soluble oligomers possessing a common three-dimensional structure found in many 
neurodegenerative diseases potently inhibit 20S and 26S proteasome gate-opening thus drasti-
cally impairing its function. While certain studies show some forms of aggregates do not impair 
the proteasome (which we also find Fig. 1 B & D), the aggregates from these studies were not 
assayed for the presence of A11+ oligomers. Based on our results we proposed the following 
mechanistic model (Fig. 6C) of how A11+ oligomers impair proteasome function: 1) A11+ oligo-
mers bind with low nM affinity (Fig. 1 & 2) to the outer surface of the -subunits along the C2 axis 
(the presumed binding site); 2) by binding to this site the oligomers stabilize the closed confor-
mation of the -subunits and prevent spontaneous gate-opening (Fig. 3); 3) activation loop-de-
pendent gate opening (e.g. PA26) occurs normally in the presence of oligomers, since its mech-
anism only requires contact between the activation loops and the base of the gating residues (Fig. 
4); 4) however, HbYX dependent gate-opening (e.g. the 19S regulatory particle or HbYX peptide) 
is inhibited as oligomer-bound -subunits are unable to undergo the conformational changes re-
quired to open the gate (Fig. 5 & 6), which are stabilized by the bound oligomer. From a general 
mechanistic perspective, in this model one expects to observe opposing allosteric controls fought 
between two allosteric modulators that bind to distinct sites on the 20S proteasome. From this 
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model, one expects to observe competition between two allosteric modulators (the HbYX motif 
and the oligomers) that bind to distinct sites on the 20S proteasome. In this sense, the HbYX motif 
is a positive allosteric modulator that induces gate opening, whereas the A11+ oligomers are 
negative allosteric modulators that induce gate closing. These diametrically opposed regulators 
thus fight to control the proteasome gate. Moreover, it appears that the HbYX mechanism is dom-
inant since binding of the non-hydrolysable ATP analog, ATPS, prevents inhibition by A11+ oli-
gomers (Fig. 6A), though further confirmation is warranted.  
These results demonstrate that oligomer-mediated impairment of proteasome function is not de-
pendent on the sequence of the misfolded protein but rather the oligomer’s three-dimensional 
shape. Specifically, we found a consistent correlation between an oligomer’s ability to impair the 
proteasome and recognition by the A11 antibody. While the physiological concentration of A11+ 
oligomers in neurons is unknown, if we consider that the affinity constant for the oligomers is low 
nM, and that the cellular concentration of the 20S is estimated to be low micromolar70 then, with 
respect to this binding reaction, the 20S is saturating in the cell. This implies toxic oligomers will 
bind to the 20S irrespective of their cellular concentration. Which begs the question: are physio-
logical levels of A11+ oligomers sufficient to impact protein degradation? Using laser capture 
microdissection and isolation of hippocampal pyramidal neurons from sporadic Alzheimer’s Dis-
ease cases, Hashimoto et al. (2010) determined the intraneuronal concentration of A42 to be 
3M71, but what proportion of the intracellular A42 is in oligomeric form is not known. Further-
more, Kisselev et. al. (2006) showed that the amount of proteasome inhibitor, Velcade™ that is 
used to treat multiply myeloma only inhibits protein degradation by about 10-25%72. This result 
demonstrates that a relatively small alteration of protein breakdown can have a substantial impact 
on cell death. Consistent with this reasoning, stereotaxic unilateral infusion of lactacystin (a se-
lective proteasome inhibitor) into the substantia nigra pars compacta of rats caused neurodegen-
erative disease like symptoms22. However, the percentage of proteasomes that must be active in 
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neurons to maintain normal proteostasis is not known and thus we could only speculate about 
what level of intracellular A11 oligomers would be required to impact neuronal function. Never-
theless, as protein degradation begins to suffer as oligomers accumulate, the level of proteasome 
impairment is expected to increase exponentially as more proteins accumulate and oligomerize. 
Such a model would be expected to exhibit exponential progression kinetics, which coincides with 
the exponential deterioration that is observed over decades in most neurodegenerative diseases. 
These results build confidence that such oligomers in neurons could impair proteasome function 
enough to contribute to the progression of these neurodegenerative diseases. 
Future efforts are required to understand which structures within the A11 epitope facilitate 20S 
proteasome binding and impairment and if this phenomenon occurs in human disease conditions. 
Elucidation of this mechanism provides a compelling model to explain why proteasome function 
has been found to be impaired in virtually all neurodegenerative diseases. Interestingly, Choi et. 
al. (2016)78 showed that opening of the 20S proteasome gate in cells leads to enhanced cellular 
proteasome function, including ubiquitin-dependent protein degradation, decreased protein ag-
gregates, and protection from oxidative stress. Our model provides a mechanistic framework to 
develop small molecules to counteract proteasome impairment via A11+ oligomers. Illustrating 
this potential mechanism of proteasome impairment identifies novel drug targets for developing 
small molecule activators of the proteasome gate. Such therapeutic interventions have the poten-
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Materials and Methods 
Proteasome purifications 
Mammalian 20S proteasomes were isolated from bovine liver as described79. Briefly, cleared liver 
homogenate was passed over DE53 column. Protein was eluted with a stepwise NaCl gradient. 
Fractions with significant proteasome activity were pooled and further separated by a strong anion 
exchange column (ResourceQ, GE Healthcare) eluting with NaCl gradient. Fractions with high 
suc-LLVY-amc hydrolysis were pooled for further purification using a hydroxyapatite column 
(CHT-I, Bio-Rad) and eluted by KPO4 gradient. Fractions with high proteasome activity were 
pooled and further purified by SEC (S-400, GE Healthcare). Eluted fractions were pooled and 
purity of 20S proteasomes (>98%) was determined by SDS-PAGE and quantified by densitometry 
(ImageJ, NIH). Mammalian 26S proteasomes were isolated from rabbit muscle using the Ubl af-
finity purification as described80. Human 26S proteasomes were affinity purified on a streptavidin 
column from the HEK293-4-biotin cell line as described78. Recombinant PA26 was expressed in 
BL21-STAR E. coli and purified by affinity with a Ni-NTA column (Qiagen), as described81. Re-
combinant human PA28 was expressed in BL21-STAR E. coli and purified by affinity with a Ni-
NTA column (Qiagen), as described82. Wild-type and mutant 3N yeast 20S proteasomes were 
expressed and purified by anion-exchange chromatography as described83. Fluorogenic sub-
strate peptides were purchased from BostonBiochem (suc-LLVY-amc) and EZBiolabs (ac-
nLPnLD-amc and ac-RLR-amc). Rpt5 peptides were synthesized by EZBiolabs. Protein concen-
trations were determined by Bradford assay (BSA standard) (Thermo Scientific). 
Proteasome activity assays – peptide substrates 
Unless otherwise specified, bovine 20S (0.5 nM), rabbit muscle 26S (0.4 nM), yeast WT 20S (1.4 
nM), or yeast 3N 20S (0.14 nM) proteasomes were assayed using fluorogenic peptides, as 
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described45in 96-well black flat bottom untreated plates (Costar). Briefly, proteasomes were incu-
bated in a reaction buffer containing 50mM Tris–HCl (pH 7.4), and 100M fluorogenic substrate 
(suc-LLVY-amc, ac-nLPnLD-amc) or 10M fluorogenic substrate (boc-LRR-amc). 20S pro-
teasomes were treated with Rpt5, or with PA28 or PA26 to induced gate opening as indicated. 
Rabbit muscle 26S proteasomes were used in the presence of 1mM DTT, 10mM MgCl2, and 
100M of fluorogenic substrate (ac-nLPnLD-amc) with either 2mM ATP (99%, Sigma) or 10M 
ATPS (95%, Sigma). Fluorescence was measured every 55 s for 120 min 
(ex/em:380nm/460nm). The rate of increase in fluorescence intensity is directly proportional to 
proteasome activity. For all experiments, an equal volume of the appropriate control buffer (iden-
tical to the aggregate/oligomer buffer that is described below) was used for controls. All molar 
concentrations of A, -Syn, and Htt-53Q are calculated based upon the monomeric protein con-
centration.  
Proteasome activity assays – protein substrates 
FITC-casein (0.08g, Sigma) and Ub4(lin)-GFP-35 (0.08g, a kind gift from Dr. Andreas Ma-
tousheck) degradation assays were carried out in 50l reactions using 96-half-well non-binding 
surface treated black plates (Corning) at 37C. The GFP substrate was generated as described84. 
Proteasomes were added to the reactions (1g 20S, or 0.9g human 26S) in the presence or 
absence of A*56 oligomers (10M) and fluorescence was measured at every 60 seconds for 90 
minutes. Data shown is the mean of three reactions, with a 5-point moving average, and error 
bars represent +/- standard deviation. Degradation rates were determined by calculating the slope 
of a line fit to the first 30 minutes of activity. 
A 1-42 peptide 
Synthetic A(1-42) was purchased from Selleckchem, Anaspec, and EZBiolabs. To remove 
preexisting aggregates, synthetic A peptide was dissolved in 100% Hexafluoroisopropanol 
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(HFIP), and incubated at 37C for 2 hours with shaking (500 RPM). The HFIP was removed and 
the remaining peptide films were stored at -80C until use. Monomeric A was obtained by dis-
solving synthetic peptide in 100% anhydrous DMSO (Thermo Scientific) at 5mM and diluted with 
PBS to a final concentration of 50M immediately prior to use. Crude A aggregates were pre-
pared as described85. A*56 oligomers were generated similar to Barghorn et al. 200559. Briefly, 
HFIP treated peptide films were resuspended in 100% anhydrous DMSO (5mM) and bath soni-
cated for twenty minutes before further dilution (400M) with 20mM NaPO4 pH 7.4, 140mM NaCl, 
0.2% SDS. The 100M A was incubated at 37C for six hours, diluted to 100M with nanopore 
H2O, incubated at 37C for 18 hours, centrifuged for 10 minutes at 3,000 g, and the supernatant 
containing A*56 oligomers was removed and dialyzed against 5mM NaPO4 pH 7.4, 35mM NaCl. 
Where indicated, A*56 oligomers were crosslinked (before dialysis) with 1mM glutaraldehyde 
(EM grade, Thermo Scientific) for 2 hours at room temperature. The reaction was quenched by 
the addition of 1M Tris-HCl pH 8 (to a final concentration of 10mM) and incubated for an additional 
30 minutes. A*56 oligomers were purified by SEC (Superose 12 10/30, GE Healthcare) and 
eluted as a single major peak. Each preparation of A*56 was confirmed to be A11+ by dot blot 
analysis as described below. To generate A-HMW A11+ oligomers, the second A incubation at 
100M was extended to 26 hours. To generate A A11+ protofibrils, the second A incubation at 
100M was extended to 50 hours. The A A11+ protofibrils eluted from the Superose 6 column 
in a single peak at the void volume and were confirmed to be >700 kDa by Native-PAGE. All 
buffers were filtered with 0.2m membranes immediately prior to use. All SEC experiments were 
performed on an ÄKTApurifier (GE Healthcare) at 4°C with 5mM NaPO4 pH 7.4, 35mM NaCl at a 
flow rate of 0.5 mL/min. A concentration was calculated by UV absorption at 280nm (molar ex-
tinction coefficient 1940 M-1 cm-1) and confirmed with Bradford protein concentration assay 




Human wild-type -Synuclein (-Syn) with N-terminal his-tag in pET28a vector was expressed 
and purified from BL21-STAR E. coli using a Ni-NTA column (Qiagen) followed by anion exchange 
chromatography (HiTrapQ, GE Healthcare). Pure -Syn monomers were obtained by SEC (Su-
perose 12 10/30, GE Healthcare) immediately prior to use. The purity of -Syn monomers (>98%) 
was determined by SDS-PAGE and quantified by densitometry (ImageJ, NIH). Crude -Syn ag-
gregates/oligomers were generated by incubating monomeric -Syn (3 mg/mL) in PBS (20mM 
NaPO4 pH 7.4, 140mM NaCl) at 37C for 7 hours. After oligomerization, the oligomers were sep-
arated from the remaining monomers by SEC (Superose 12, GE Healthcare) and verified A11+ 
by dot blot.  
Huntingtin protein 
GST-tagged huntingtin exon1 constructs with a 53 polyglutamine repeat (GST-Htt-53Q) and a 20 
polyglutamine repeat (GST-Htt-20Q). Protein was expressed and purified from BL21-STAR E. 
coli as described86. Briefly, the GST-fusion protein was cleaved with PreScission Protease (GE 
Healthcare) at 4C according to manufacturer protocol. The free Htt-53Q proteins were further 
purified by SEC (Superose 12 10/30, GE Healthcare) to obtain a monomeric population immedi-
ately prior to oligomerization. The purity of Htt-53Q monomers (>95%) was analyzed with SDS-
PAGE quantified by densitometry (ImageJ, NIH). Oligomers were generated by incubating mon-
omeric Htt-53Q (1mg/mL) at 37C for 1 hr. Due to the rapid formation of Htt-53Q oligomers, mon-
omeric Htt-20Q (which oligomerized at a much slower rate) was used for the monomer assay in 
Figure 1B.  
Crude aggregate fractionation 
Insoluble aggregates were removed from crude aggregate preparations by centrifugation at 
10,000 x g for 10 minutes. The supernatant containing soluble oligomers was transferred to a 
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fresh Eppendorf tube and the remaining pellet was gently resuspended in PBS. The pellet fraction 
was centrifuged twice more before final resuspension at 1mg/mL in PBS. The fibrillar nature of 
the insoluble fraction was confirmed by Thioflavin-T (Sigma)  fluorescence in comparison to mon-
omer preparation controls as described below. 
SDS-PAGE and Native-PAGE 
Proteins were separated by SDS-PAGE using NuPAGE™ 4-12% Bis-Tris Protein Gels (Invitro-
gen), or separated by Native-PAGE using Novex™ 10-20% Tris-Glycine or NuPAGE™ 3-8% Tris-
Acetate Protein Gels (Invitrogen), as indicated. Total protein was visualized with coomassie stain 
(Simply Blue Safe Stain, Novex) or silver stain (Pierce Silver Stain kit, Thermo Scientific) as indi-
cated according to manufacturer instructions. Immunoblots were performed as described below. 
Native-PAGE in-gel 26S proteasome activity assay was performed using NuPAGE™ 3-8% Tris-
Acetate gels (Invitrogen). Samples were mixed with Novex™ Tris-Glycine Native Sample Buffer 
(2X) (Invitrogen) just before loading. Electrophoresis was carried out in Novex™ Tris-Glycine Na-
tive Running Buffer (Invitrogen) (with 0.5mM DTT, 1mM ATP, and 5mM MgCl2) at 4°C and 150V 
for 4 hours. Native gels containing 26S proteasomes were incubated with reaction buffer (50mM 
Tris pH 7.5, 10mM MgCl2, 2mM ATP, 1mM DTT, 50M suc-LLVY-AMC) for 30 min at 37°C. Flu-
orescent bands around proteasomes were visualized by standard gel-imaging systems for DNA 
staining by ethidium bromide.  
Immunoblotting 
For Native-PAGE Western blots, proteins were transferred to nitrocellulose membrane (GE) using 
tris-glycine transfer buffer (Novex). Primary antibodies were purchased from Invitrogen (anti-oli-
gomer A11, and anti-A N-terminus clone NAB228) and diluted 1:1000 in TBST (50mM tris, 150 
mM NaCl, 0.01% Tween-20) + 5% nonfat milk prior to use. AlexaFluor-647 conjugated secondary 
antibodies (Invitrogen) were diluted 1:3500 in TBST prior to use. Membranes were blocked for 1 
hour at room temperature in TBST + 10% nonfat milk, briefly washed with TBST, incubated with 
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primary antibody for 1 hour at room temperature, washed with TBST (3 x 5 minutes), incubated 
with secondary antibody for 1 hour at room temperature, washed (3 x 5 minutes), and imaged on 
a Molecular Dynamics Typhoon 9410 Variable Mode Imager. Dot blots were performed by spot-
ting protein on 0.1M nitrocellulose membranes and processed the same as Western blots.  
Antibody neutralization assays 
Anti-oligomer A11 (Invitrogen) and A N-terminal antibody (clone NAB228, Invitrogen) were buffer 
exchanged to 50mM Tris (pH 7.4) with Zeba spin desalting columns (Thermo Scientific). The 
antibodies (0.5g) were incubated with A*56 (50M) or control buffer for 25 minutes at 37C 
before adding to proteasome activity assays.  
Crosslinking A*56 and 20S proteasomes 
Mammalian 20S proteasomes were buffer exchanged to 10mM NaPO4 (pH 7 with Zeba spin de-
salting columns (Thermo Scientific) and incubated with A*56 oligomers (or an equal volume of 
control buffer) for 45 minutes at 37C. 1mM Glutaraldehyde was added to the mixture of 20S 
proteasomes and Aβ*56 oligomers and incubated for 5 minutes at 37C. Crosslinking reactions 
were quenched by the addition of 1M Tris-HCl pH 8 (1mM). Proteins were separated by SDS-
PAGE and Native-PAGE and visualized with silver stain or immunoblotting as described above.  
Oligomer characterization 
For atomic force microcopy imaging, preformed A oligomers were deposited on freshly cleaved 
mica (Ted Pella Inc., Redding, CA) and allowed to sit for 30 s. The mica substrate was then 
washed with 200L of ultrapure water and dried with a gentle stream of nitrogen. Samples were 
imaged in tapping mode via ex situ AFM using a Nanoscope V MultiMode scanning probe micro-
scope (Veeco, Santa Barbara, CA). AFM images were analyzed with Matlab equipped with the 
image processing toolbox (Mathworks, Natick, MA). For negative stain electron microscopy, 6l 
108 
 
of preformed A*56 oligomers were applied to ultra-thin copper 400 mesh carbon grids (Electron 
Microscopy Sciences) and imaged on a JEOL JEM-2100 Transmission Electron Microscope.  
Thioflavin-T florescence measurement 
Thioflavin-T (ThT) (Sigma) was dissolved (1mM) in PBS, filtered through a 0.2M syringe filter, 
and stored at -20°C until use. For the assays, 3g of A was incubated at room temperature for 
10 minutes in 100M of PBS with 20M ThT and fluorescence was measured (ex/em: 
450nm/490nm) in a Synergy2 plate reader (GenTek).  
Statistical analysis 
Data were analyzed using an unpaired Student’s t-test (Prism). For all statistical analyses, a value 
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Proteostasis is maintained by several systems in the cell including the ubiquitin-proteasome sys-
tem (UPS), chaperones, chaperone-mediated autophagy, and macroautophagy. The UPS is the 
principle route for the degradation of intracellular misfolded, damaged, or unneeded proteins. At 
the center of the UPS is the proteasome, a large and complex molecular machine containing a 
multicatalytic protease complex. When the efficiency of this proteostasis systems is perturbed, 
misfolded and damaged protein aggregates can accumulate to toxic levels and cause neuronal 
dysfunction, which may underlie many neurodegenerative diseases. The 20S proteasome sub-
strate-entry gate plays a critical role in proteasome function and in cellular proteostasis and the 
molecular mechanisms of gating remain poorly understood. In this study  we develop a novel 
compound that promotes proteasome gate opening to increase the degradation rate of peptides 
and proteins. These results provide a new tool for investigating proteasome function and provide 










The ubiquitin-proteasome system (UPS) is responsible for more regulated protein degradation in 
eukaryotes and regulates myriad cellular processes, such as the cell cycle, apoptosis, the immune 
response, inflammation, and the response to proteotoxic stress1,2. Proteins selected for degrada-
tion are typically modified by the covalent attachment of ubiquitin chains, which targets it to the 
26S proteasomes for degradation2,3. The 26S proteasome is a complex and highly regulated 2.5 
MDa peptidase complex, comprised of a barrel-shaped proteolytic 20S core particle with a 19S 
ATPase regulatory particle capped on one or both barrel ends4. Ubiquitinated proteins are de-
graded in a multistep process; the 19S regulatory particle binds ubiquitinated substrates, opens 
a substrate entry gate in the 20S5,6, and unfolds its substrates by linearly translocating them into 
the 20S catalytic chamber where they are degraded to peptides4,7. 
Compartmentalized proteases protect the cellular milieu from proteolytic activity and retain the 
capacity to degrade specific proteins in a regulated manner. Eukaryotic 20S proteasomes have 
four stacked heteroheptameric rings arranged in an α1-7-β1-7-β1-7-α1-7 fashion8. The two β rings 
form a catalytic chamber with three different peptidase activities (chymotrypsin-like site (β5) pref-
erentially cleaves after hydrophobic residues, the trypsin-like site (β2) preferentially cleaves after 
basic residues, and the caspase-like site (β1) preferentially cleaves after acidic residues4,9). The 
α subunits’ amino(N)-termini extend over the 13 Angstrom central pore and form a gate, which 
occludes access to the proteolytic sites located inside10,11. The 20S proteasome substrate-entry 
gate plays a critical role in proteasome function and in cellular proteostasis. The α3 N-terminus is 
the lynchpin and forms salt bridges with neighboring N-termini to stabilize the closed gate confir-
mation12. Deletion of the first eight α3 residues α3∆N  (α3∆N-20S) sufficiently destabilizes the 
closed-gate conformation and accelerates the entry and degradation of peptides12. Wild type 20S 
proteasome activity is similarly accelerated when bound to a proteasome activator (e.g. 




Proteasome activators bind to one or both ends of the 20S core particle by inserting one or more 
C-termini into pockets between adjacent 20S α subunits (intersubunit pockets). Proteasome acti-
vators stabilize the conserved proline reverse turn (at the base of the N-termini gate) in the “open” 
conformation, using two different mechanisms. Most proteasome activators’ C-termini 
(19S/PA700, Blm10/PA200, PAN) contain a hydrophobic-tyrosine-X (HbYX) motif  (Figure 1A,B). 
The penultimate tyrosine forms a hydrogen bond with the proline reverse turn to stabilize the open 
conformation and trigger gate opening14,15. In contrast, the C-termini of 11S/PA28/PA26 family of 
proteasome activators do not have a HbYX motif, instead they use an internal activation loop to 
contact and reposition the proline reverse turn16.  
Recent structural studies (cryo-EM) of the eukaryotic 26S proteasome highlight the complexities 
of 26S gate opening. Several studies suggest that the conserved HbYX motif of three 19S subu-
nits (Rpt2,Rpt3,Rpt5) stably insert into the intersubunit pockets without causing full gate open-
ing17–20.  In contrast, functional studies have shown that 19S binding to the 20S stimulates gate-
opening in the 20S proteasome6,21, in a HbYX motif dependent manner22, and binding of the HbYX 
motif by itself (as a hepta-peptide) is also sufficient to allosterically induce conformational changes 
in the α-subunits that cause gate opening14,15. Hence, the molecular mechanism of gating by the 
RP and how the gate dynamics change when a the 20S associates with an activator remains 
poorly understood. Drugs or genetic mutations that increase proteasome activity restore proteo-
stasis in cellular models of neurodegenerative disease23–25.  Therefore, there is a need for a better 
understanding of the 20S gate mechanism. 
In this study we design a small proteasome activator (ZYA) based on the molecular interactions 
of the conserved C-terminal HbYX motif in proteasome activators. We show that ZYA activates 
proteasome function by opening the 20S gate to increase degradation of both peptide and protein 
substrates. ZYA has potential application as a research tool to study proteasome function in vitro 
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and in vivo, and we demonstrate the feasibility of designing drug-like molecules to activate pro-
teasome function to treat patients with neurodegenerative diseases. 
Figure 1. Proteasome activators - HbYX motif docking into 20S α ring. A. Surface representation of 20S proteasomes in 
complex with activators [Human 26S (PDB 6msk), yeast 20S+Blm10 (PDB 4v7o), archaeal 20S + PAN (PDB 6hed)]. HbYX motifs 
visible are colored vermillion and adjacent α-subunits of the visible HbYX motif are shown in color. B. Surface representation of 
20S a rings from (A). Proteasome activator C-termini with HbYX motif bound to α-intersubunit pockets are vermillion (surface). C. 
Overlay of 20S intersubunit pockets (cartoon) from (B) with HbYX motif residues (sticks). Crystal structure of PAN C-terminus 













Yeast 20S proteasome 




















































Results and Discussion 
The conserved HbYX motif is found in proteasome activators from archaea to humans. We 
aligned activator-bound intersubunit α pockets from human (PDB 6msk17, cryo-EM), yeast (PDB 
4v7o26), and archaeal proteasomes (PDB 6hed27, cryo-EM) (Figure 1C). As expected, the C-ter-
minal HbYX motif bound to the intersubunit pockets in similar orientations, with the C-terminal 
carboxylic acid directed towards the conserved pocket lysine (which is required for 20S pro-
teasome-activator complex formation14) and the penultimate tyrosine hydroxyl group oriented to-
ward the proline reverse turn (located at the gate base). These two interactions are critical for 
HbYX motif binding to and activating the proteasome gate14,15,28. Our aim was to further charac-
terize the HbYX binding pocket and apply this information to the design of small synthetic gate 
activating molecules.  
The intersubunit pockets contain many conserved residues, some of which are known to be im-
portant for gate activation (e.g. Pro17, Lys66)28,29. We investigated the effect of mutations to three 
conserved residues positioned near the bound HbYX motif (Figure 2A). For mutational analysis, 
we used the archaeal (Thermoplasma acidophilum) 20S because it is a homoheptamer, amena-
ble to mutational studies, and easily expressed in E.coli. Consistent with previously published 
results14, Lys66Ala mutation prevented PAN30 (the archaeal homologue of the 19S) activation of 
the 20S (Figure 2B). Lys33 is located at the base of the α-helix leading toward the proline reverse 
turn. When K33 is mutated to a glycine, 20S activity was less than half that of the wild type and 
was not stimulated by PAN. This could be due to a disruption of the helices by inserting the sec-
ondary structure-destabilizing glycine, or by loss of the K33 ε-amine bonding interactions. Leucine 
81 forms the bottom of the HbYX pocket directly underneath the HbYX tyrosine. Loss of this 
hydrophobic residue (by mutation to alanine or glycine) prevents PAN mediated proteasome ac-
tivation (Figure 2B), suggesting this residue is important for stabilizing HbYX motif binding. We 
noted the proximity of Leu81 to the reverse turn backbone (Gly19). Considering the importance 
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of HbYX tyrosine hydrogen bonding with the backbone, we asked if a tyrosine substitution at this 
position would mimic the effect of a bound HbYX motif. Surprisingly, proteasomes with the 
Leu81Tyr mutation (αL81YT20S) had over three-fold greater basal activity compared to wild type 
(Figure 2C), suggesting this mutation stabilizes the open-gate conformation. In agreement with 
this, addition of PAN to αL81YT20S proteasomes only resulted in 30% increased activation, 
whereas an equal amount of PAN increased wild-type T20S activity greater than five-fold (Figure 
2C). These data show that 20S gate activation can be achieved by small scale alteration of the 
intersubunit pocket.  
Figure 2. Highly con-
served α-intersubunit 
pocket residues are re-
quired for PAN-HbYX 
gate activation. A. Multi-
ple sequences alignment 
(20S α6 protein) gener-
ated with CLUSTAL 
OMEGA (1.2.4). B. Left, 
conserved residues inter-
acting with the bound 
HbYX motif (sticks) are 
shown in the t20S inter-
subunit binding pocket 
(PDB 3ipm). The PAN 
HbYX motif (LYR) is 
shown in cyan (stick). 
Right, t20S proteasome 
(0.2 µg of wild-type or 
K66/K33/L81 mutants) 
and fluorogenic octapep-
tide (LFP) are incubated 
with or without PAN and 
ATPγS. The stimulation of 
gate opening was meas-
ured by the increase of 
LFP hydrolysis (rfu/min) 
over wild-type 20S without 
any activator. C. Left, 
same as (B), with L81 mu-
tated to tyrosine (magenta 
stick). Right, experiments 
with t20S proteasome (0.2 
µg of wild-type or L81Y 
mutant) performed same 
as in (B). Images in (B) 
and (C) were rendered 
with PyMOL. The data are 
representative of three or 
more independent experi-
ments performed in tripli-
cate. Error bars repre-
sent ± standard  deviation. 
Panels B and C: 
***p<0.0001; ns p>0.05. 
(students t test), P-value 





Previous studies showed that short (3-6 amino acid) peptides with a C-terminal HbYX motif (cor-
responding to the PAN C-terminus) did not activate the 20S gate14,15. This contrasts with our 
Leu81Tyr mutation data, from which we hypothesized small HbYX motif peptides can activate the 
gate. The 3-8 amino acid peptides used in Smith et al. (2007)14 were synthesized with unmodified 
N-termini, and this positive charge may prevent shorter HbYX peptides from binding in the inter-
subunit pocket. To test this hypothesis, we synthesized N-terminal acetylated peptides corre-
sponding to the PAN C-terminus from three to eight residues in length (CT3-8). In contrast to 
previous results14, PAN CT peptides shorter than seven residues stabilized the open 20S gate 
(Figure 3A). Based on the successful gate-activation of PAN CT3 (Ac-LYR), we designed a small, 
novel dipeptide to mimic the HbYX-motif. We substituted an alanine in place of the bulky arginine 
residue to decrease the dipeptide size, as this substitution did not alter ability of PAN-CT8 peptide 
to bind α intersubunit pockets and open the gate14,15 in previous studies. Capping the tyrosine N-
Figure 3. HbYX of pep-
tides of different lengths 
to stimulate gate opening. 
A. Peptides (200 µM) were 
incubated with 0.2 µg t20S 
proteasomes and 10 µM 
LFP substrate. A correction 
was made because the 
added peptides also com-
pete with LFP at the active 
sites. To determine the ac-
tual percentage stimulation 
of LFP hydrolysis due to 
gate opening, the ability of 
the various peptides to in-
hibit LFP hydrolysis by the 
gateless (2–12) 20S pro-
teasome was also meas-
ured, and the values were 
used to normalize data on 
LFP hydrolysis by wild-type 
20S proteasomes. Without 
normalization, the three- to 
five-residue peptides still 
stimulated 20S pro-
teasomes 2- to 3-fold. B. 
0.2 µg t20S proteasomes 
incubated with 10 µM LFP 
substrate and DMSO or 200 
µM ZYA. LFP degradation 
rate (rfu/min) is normalized 
to DMSO. The data are rep-
resentative of three or more 
independent experiments 
performed in triplicate. Error 
bars represent ± standard 
deviation. ***p<0.0001; 
**p<0.01 (student t test), P-
value compared to DMSO. 
 
(200 µM ) 
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terminus with a carboxybenzyl group allowed the synthesis of a dipeptide that retained a hydro-
phobic group preceding the tyrosine. We tested ZYA with T20S proteasomes and observed al-
most 6-fold activation (Figure 3B).  
Our next step was to test ZYA with the more com-
plex heteroheptameric 20S proteasomes found 
in eukaryotes. Consistent with our previous re-
sults, ZYA activated the mammalian 20S pro-
teasome (Figure 4A). When the charged carbox-
ylic acid was modified with NOH2 group, (i.e. no 
longer carried a negative charge) ZYA-[NOH2] 
failed to activate the proteasome (Figure 4A). 
Since the charged C-terminus is critical for HbYX 
mediate gate activation, we evaluated the effect 
of adding additional negative charges to the 
HbYX-motif dipeptide (ZYD, ZYE), a backbone 
torsion constraint (ZYP), and a polar group 
(ZYQ). None of these “X” modifications activated 
the mammalian 20S proteasome (Figure 4A).  
Since hydrogen bonding between the HbYX hy-
droxyl group and G19 in the proline reverse turn 
is important for gate activation by proteasome 
activators and their C-terminal peptides31, we de-
termined the effect of modifying the ZYA tyro-
sine. The tripeptide Ac-YFA partially activated 
the 20S proteasome gate (Figure 4B). Although 
Figure 4. Effect of ZYA derivatives on proteasome gate 
activation. A. Mammalian 20S proteasome activity 
(nLPnLD-amc hydrolysis, rfu/min) with the indicated ZYA 
derivatives at 250 M. Proteasome activity is normalized to 
DMSO. B. Mammalian 20S proteasome activity (nLPnLD-
amc hydrolysis, rfu/min) with the indicated ZYA derivatives 
at 100 M. Ac, acetylated; nitro-Tyr, nitrotyrosine; pY, 
phosphotyrosine, 4-amino-Phe, 4-Amino-L-phenylalanine. 
Proteasome activity is normalized to DMSO. The data are 
representative of three or more independent experiments 
performed in triplicate. Error bars represent ± standard de-
viation. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns 
p>0.05 (student t test, P-value compared to DMSO). 
‡p<0.05 (student t test, P-value compared between two 
groups as indicated by brackets). 
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not a strict C-terminal HbYX motif, this peptide retains a tyrosine, and it is worth noting that some 
eukaryotic proteasome activators have a -YYA HbYX motif (i.e. human Rpt5, yeast Blm10). The 
ability of Ac-YFA to activate the proteasome gate suggests the intersubunit binding pocket is 
“flexible” as to what peptides it can successfully bind. Modifications disrupting hydrogen bond 
Figure 5. ZYA activates the proteasome 
gate. A. ZYA (green sticks) docked into the 
human 5/6 intersubunit pocket. Conserved 
G19 and K62 (corresponding to K66 in T. ac-
idophilum 20S) shown as cyan sticks. Yellow 
arrow points to L81. Image was rendered in 
PyMOL. B. Mammalian 20S proteasomes 
(0.5 nM) were incubated with 1 mM ZYA and 
100 µM of the indicated peptide substrate. 
Proteasome activity (linear rate of substrate-
amc hydrolysis) is normalized to DMSO con-
trols. C. Yeast wild-type and gate mutant 
α3∆N 20S proteasomes incubated with 500 
µM ZYA. Proteasome activity (linear rate of 
nLPnLD-amc hydrolysis) is normalized to 
DMSO controls. D. Mammalian 20S pro-
teasomes (0.5 nM) were incubated with ZYA 
at the indicated concentrations. Proteasome 
activity (linear rate of substrate-amc hydroly-
sis) is normalized to DMSO control. The data 
are representative of three or more inde-
pendent experiments performed in triplicate. 
Error bars represent ± standard deviation. 
Panels B and C: ****p<0.0001; ***p<0.001; 










donating availability of the ZYA tyrosine hydroxyl group (Z-pY-A and Z-[3,nitroTyr]-A) do not acti-
vate the proteasome (Figure 4B). Interestingly, when 4-aminophenylalanine is substituted for the 
tyrosine (Z-[4,aminoPhe]-A) the proteasome is activated like ZYA (Figure 4B). Unlike phosphoty-
rosine and 3-nitrotyrosine, 4-aminophenylalanine’s mass and polar surface area is like tyrosine’s, 
and it has the same hydrogen bond availability. These results are consistent with the computa-
tional docking model of ZYA in the human α 5/6 intersubunit pocket (Figure 5A).  
Our next aim was to use biochemical methods to confirm ZYA activates the 20S proteasome by 
stabilizing the open gate conformation. Eukaryotic proteasomes have three different types of ac-
tive sites, and stabilization of the open gate conformation increases activity from all three sites. 
We tested the effect of ZYA on proteasome hydrolysis of three substrates preferentially cleaved 
by different sites (LLVY-amc, β5; nLPnLD-amc, β1; LRR-amc, β2). As expected, ZYA increased 
the hydrolysis rate of all three substrate peptides (Figure 5B). To confirm ZYA indeed influences 
the 20S gate, we performed activity assays using yeast 20S proteasomes with a gate mutation 
(α3∆N) that prevents the gate from fully closing10. The α3∆N proteasome gates allow substrate 
peptides unrestricted access to the proteolytic core. While ZYA activates wild-type yeast pro-
teasome activity, it does not increase α3∆N proteasome activity (Figure 5C). We titrated ZYA with 
20S proteasomes to determine maximum activation and affinity. Although ZYA can stimulate pro-
teasome activity over 40-fold, it has poor affinity (Figure 5D). Interestingly, ZYA has hill coefficient 
of 1.5 indicative of positive cooperative binding, which matches recently proposed cryo-EM struc-
tural models for 19S RPT C-termini opening the gate17–20.  
While we have demonstrated ZYA activates peptide hydrolysis via opening its gate, changes in 
peptidase activity do not necessarily reflect changes in the proteasome’s capacity to degrade 
proteins. To evaluate the efficacy of ZYA to stimulate protein degradation, we used SDS-PAGE 
to measure the effect of ZYA has on proteasome degradation of tau23 (a truncated tau protein) 
and casein, which are protein substrates of the 20S. ZYA significantly increased the degradation  
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of both proteins (Figure 6A). In support of these results, we measured 20S proteasome degrada-
tion of β-casein (Figure 6B). In agreement with the gel-based protein degradation assay, ZYA 
significantly increased proteasome degradation β-casein.  
Thus far we have demonstrated ZYA increases peptide and protein degradation by increasing 
20S proteasome gate-opening. We recently published a study demonstrating protein oligomers 
associated with neurodegenerative diseases (Aβ, α-synuclein, and huntingtin with a Q53 expan-




Figure 6. ZYA activates protein degradation and prevent proteasome impairment by neurodegenerative-disease associ-
ated oligomers. A. Mammalian 20S proteasomes incubated with tau23 (truncated tau protein) or β-casein. At the indicated times, 
the reaction was quenched by addition of SDS loading buffer and separated by SDS-PAGE. Proteins visualized with Coomassie 
brilliant blue. Gels are representative of three independent experiments. 20S proteasome subunits are indicated with brackets to 
serve as loading controls for each sample. B. Mammalian 20S proteasomes (2 µg) incubated with fluorescamine labeled β-casein 
(2 µg) and DMSO or 2 mM ZYA for 35 min. The acid-soluble degradation products were measured by using the fluorescamine 
reaction. Values are means ± SD of three experiments. C. Mammalian 20S proteasome (0.5 nM) activity (nLPnLD-amc hydrolysis, 
rfu/min) with ZYA at the indicated concentrations, with and without A*56 (0.5 M) oligomers (Thibaudeau et al., 2018). D. Mam-
malian 20S proteasomes (0.5 nM) incubated with and without -Syn [top] or Htt-Q53 [bottom] oligomers (Thibaudeau et al., 2018) 
and DMSO or ZYA (1 mM). Rate of nLPnLD-amc hydrolysis is normalized to the control. The data are representative of three or 
more independent experiments performed in triplicate. Error bars represent ± standard deviation. ***p<0.001; **p<0.01; *p<0.05; 





showed an 8-amino acid HbYX peptide derived from the Rpt5 C-terminus partially restored pro-
teasome activity in the presence of these oligomers. Remarkably, when proteasome activity is 
measured in the presence of oligomers, the addition of ZYA completely restores proteasome 
function (Figure 6C). This is an important demonstration for the potential small molecules to re-
store activity in conditions of proteasome impairment.  
Concluding Remarks 
The proteasome is a highly regulated multi-subunit complex and possesses multiple drug targets 
to modulate its degradation capacity. The first compounds to target the proteasome inhibited the 
proteolytic sites in the 20S core particle. In fact, early understanding of the importance of the 
proteasome for biological functions and processes rapidly advanced with the introduction of the 
first proteasome inhibitors32. More recently, compounds targeting a 19S-associated deubiquiti-
nase (USP14) have been developed. Treatment of cultured cells with these inhibitors can in-
crease the rate of degradation of a subset of proteasome substrates33, and accelerate the rate of 
degradation of wild-type and pathological tau mutants34. In contrast, development of compounds 
to stimulate gate-opening have received little attention. Recent structural studies (cryoEM) of the 
eukaryotic 26S proteasome highlight the complexities of 26S gate opening. Considering the im-
portance of the proteasome gate in regulating protein degradation, gate-activating compounds 
(such as ZYA) have great potential as research tools to probe proteasome function in vitro and in 
vivo.  
Decreased proteasome function has been reported in a broad array of chronic neurodegenerative 
diseases35, and proteasomal upregulation accelerates the clearance of pathogenic proteins. Stud-
ies suggest the elevation of proteasomal activity is tolerable to cells and may be beneficial to 
prevent the accumulation of protein aggregates. For example, Cells treated with exogenous pro-
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teasomes are more efficient in degrading overexpressed human tau than endogenous pro-
teasomal substrates, resulting in decreased levels of tau aggregates36. Similar results are seen 
in cells expressing the α3∆N open gate mutant proteasome37. Our study offers proof of concept 
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Materials and Methods 
Proteins and peptides 
T.acidophilum wild type 20S and Δα2-12 20S proteasomes were purified as described30. All 20S 
mutants were generated by overlapping PCR site-directed mutagenesis. The plasmid for M.jan-
naschii PAN(M74A), kindly provided by Dr. Peter Zwickl30, lacked a His Tag and was purified as 
described38, but Tris buffers were made at 50 mM instead of 20mM. Mammalian 20S pro-
teasomes were isolated from bovine liver as described39. Wild type and mutant α3ΔN yeast 
20S proteasomes were expressed and purified by anion-exchange chromatography as de-
scribed40. Fluorogenic substrate peptides were purchased from BostonBiochem (suc-LLVY-
amc) and EZBiolabs (ac-nLPnLD-amc, ac-RLR-amc, LFP (Mca-AKVYPYPME-Dpa(Dnp)-am-
ide)), PAN CT peptides, ZYA, and ZYA derivatives were purchased from Abclonal. Oligomers 
of Aβ*56, α-synuclein, and huntingtin-Q53 were prepared as described41. All oligomers used 
were recognized by the α-oligomer antibody, A1142. Protein concentrations were determined 
by Bradford assay (Thermo Scientific).   
Enzyme assays 
To measure peptide hydrolysis, fluorogenic peptides in DMSO were used at a final concentration 
of 100 μM for Suc-LLVY-amc and Ac-nLPnLD-amc, and 10 μM for LFP and Boc-RLR-amc, in 50 
mM Tris (pH 7.5), 1 mM DTT. For archaeal 20S, LFP peptides were added to the buffer at 
45°C, and where indicated, 1 μg of PAN and 10 µM ATPγS (+5 mM MgCl2) was added to the 0.1 
ml of reaction buffer (sufficient to saturate the 20S particles)43. Assays with mammalian (0.5 nM 
and 1 nM as indicated), yeast wild-type (2 nM), and yeast α3∆N (0.2 nM) proteasomes were 




Degradation of proteins 
Tau23 or β-casein were incubated with mammalian 20S proteasomes for the indicated time at 
37oC. Reactions were quenched by addition of LDS sample buffer (Invitrogen). Proteins were 
separated by SDS-PAGE using NuPAGE™ 4–12% Bis-Tris protein gels (Invitrogen) and visu-
alized with coomassie brilliant blue. The degradation products from β-casein were measured by 
using the fluorescamine reaction, as described previously43.  
Statistical analysis 
Data were analyzed using an unpaired Student’s t-test (Prism). For all statistical analyses, a value 
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General Discussion  
The structural evolution of regulated proteases was driven by the need to protect proteolytic ac-
tivity from the cellular milieu, but still have the capacity to degrade select proteins in a regulated 
manner. The substrate-entry gate in the 20S proteasome thus plays a critical role in proteasome 
function and in cellular proteostasis. Maintaining proteostasis is especially important for neurons 
due to their complex architecture, long lifespan, and inability to dilute aggregate load by cell divi-
sion1. Moreover, proteasomal degradation is critical for normal functioning of neuronal synapses, 
including synaptic protein turnover, plasticity, and long-term memory formation, which rely on 
tightly controlled changes in the proteome1–4. As dysfunction in proteasomal degradation has 
been implicated in many human diseases, biochemical and structural analysis of the proteasome 
is essential to advance our understanding of its action and regulation mechanisms.  
I. Mechanism of proteasome impairment by protein oligomers 
It is well established that proteasome function is decreased in neurodegenerative diseases, and 
impaired function has been implicated in the development of many neurodegenerative diseases, 
including Alzheimer’s, Parkinson’s, and Huntington’s disease5–9. Study 1 identified a common 
mechanism of proteasome impairment by neurodegenerative disease associated protein oligo-
mers. We showed that oligomers from three different ND associated proteins adopt a similar 3D 
conformation and stabilize the proteasome 
gate in the closed conformation, thereby re-
stricting substrate entry into the catalytic 20S 
proteasome core. Taken together, biochemical 
data from Study 1 suggests oligomers stabilize 
the closed gate by binding to the -intersubunit 
cleft on the side of the proteasome (Figure 1).  
Figure 1. Proposed mechanism of oligomer-mediated pro-
teasome impairment. Oligomers with the A11 conformation 
bind to the intersubunit pocket and stabilize the closed gate. 




I.A. Targeting oligomer-proteasome interactions 
Protein-protein interactions (PPIs) represent a vast class of therapeutic targets both inside and 
outside the cell. Twenty years ago, PPIs were deemed intractable drug targets10. Thanks to recent 
advances in our understanding of PPIs, more than 40 PPIs have been targeted and several PPI-
inhibitors have reached clinical trials11–13. Increased proteasome activity has been shown to have 
a protective cellular effect and extend lifespan14–17, therefore preventing oligomer-proteasome in-
teractions has the potential to restore proteasome function in neurodegenerative disease. Under-
standing the structural interactions of oligomers with the proteasome is the foundation for design-
ing protein-protein interaction (PPI) inhibitors that prevent oligomers from binding to the pro-
teasome.  
Mass spectrometry combined with hydrogen/deuterium (H/D) exchange is used to study the con-
formation and dynamics of proteins. H/D exchange can be used in a comparative manner to iden-
tify changes in protein conformation and dynamics induced by ligand binding or protein-protein 
interactions18,19. Analysis of oligomer-proteasome interactions with H/D exchange techniques can 
provide identification of the oligomer binding site, and further elucidate changes in proteasome 
gate dynamics due to oligomer-proteasome interactions. 
Chemical crosslinking is another important tool for mapping protein three-dimensional structures 
and protein-protein interactions20. In recent years, new crosslinking/mass spectrometry (XL-MS) 
approaches have been developed to study proteasome structural conformations and proteasome-
interacting proteins21–23. For example, using two cross-linkers, bis (sulfosuccinimidyl) suberate  
and its water-insoluble analog disuccinimidyl suberate (DSS), Song et al. (2016) mapped the 
noncovalent interactions among 20S proteasome subunits in breast cancer cells21. Using a disuc-
cinimidyl sulfoxide-based (DSSO) cross-linking and mass spectrometry platform, Wang et al. 
(2017) mapped the interactions of Ecm29 within itself and with proteasome subunits and deter-
mined the architecture of the Ecm29-proteasome complex with integrative structure modeling23.  
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Thus, HD exchange and XL-MS chemical crosslinking approaches can potentially identify and 
structurally characterize the oligomer binding site on the proteasome. The potential druggability 
of the oligomer-proteasome interaction can be assessed by analysis of the geometrical parame-
ters and residue properties of the binding site11.  
II. Proteasome gate activation by synthetic molecules 
Study 2 characterized the mechanism of HbYX induced proteasome gate opening and identified 
HbYX-based di-peptides as proteasome gate-activators. Notably, we developed a novel HbYX 
dipeptide, ZYA (Figure 2). ZYA promotes proteasome gate opening and rescues proteasome ac-
tivity from oligomer-mediated impairment, supporting the HbYX mechanism as a potential drug 
target to restore proteasome activity in neurodegenerative diseases. These data provide a mech-
anistic framework to develop 
small molecules directly activate 
the proteasome gate, thereby in-
creasing proteasome activity and 
protein degradation.  
II.A. Mechanism of HbYX-motif proteasome gate opening 
Detailed knowledge of the HbYX gate mechanism is essential for the rational design of gate-
activating molecules. The first proteasome gating studies identified the mechanism of pro-
teasomal ATPase-induced gate opening in the 20S by studying the archaeal 20S-PAN ATPase 
(archaeal homolog of 19S ATPases) complex. The Goldberg Lab and colleagues demonstrated 
that docking of the PAN ATPases’ C-termini (containing the conserved HbYX motif) in to the 20S 
proteasome α-ring opens the 20S gate by a “key-in-a-lock” mechanism24–26.  Furthermore, seven-
residue or longer peptides from PAN’s C-terminus containing the HbYX motif can by themselves 
cause a rotation of the α-subunits to induce gate opening26. The process of 19S-20S complex 
formation and gate opening is much more complex than PAN-20S interactions, due to the 
20S 
+ 
Figure 2. Activation of the proteasome gate with ZYA.  
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presence of six different 19S ATPases with distinct C-termini and seven distinct α-intersubunit 
pockets in the eukaryotic 20S proteasomes. Nonetheless, the HbYX motif “key-in-a-lock” mech-
anism appeared to be conserved from archaea to mammalian proteasomes as gate opening could 
be induced by seven-residue peptides from the 19S ATPase subunits C-termini (Rpt2 and Rpt5, 
containing the HbYX motif)25.  
Recent single-particle cryo-electron microscopy (cryo-EM) studies of yeast and human 26S pro-
teasomes have revealed a complex mechanism for the 19S ATPase hydrolysis cycle, gate open-
ing, substrate unfolding and translocation into the 20S core28-34. These studies have presented 
structures of multiple 26S conformational states during the ATP hydrolysis cycle and substrate 
processing, the majority of which have a closed 20S gate. Several structures show 19S ATPase 
C-termini containing the HbYX motif (Rpt 5 and 3, plus Rpt 2 in some conformational states) 
docked into α-intersubunit pockets in the absence of gate-opening. These data have been inter-
ested as evidence that the HbYX motif alone does not induce gate opening in eukaryotic pro-
teasomes.  
It is worth noting that cryo-EM analysis pf the 26S proteasome is not without experimental uncer-
tainty. Single-particle EM depends on the computational averaging of thousands of images of 
identical particles27. Since the 26S proteasome adopts many different conformations during the 
ATP hydrolysis cycle, more homogeneous subsets of 26 conformations are generated using 2D 
and 3D classification procedures prior to computational averaging of the particle subset. None-
theless, the resultant 26S molecular structure is still derived from the averaged density of 10,000 
to > 200,000 26S particles28. Averaging a subset of proteasome particles can obscure open-gated 
proteasomes if they are a minority within the subset. Although one or more 19S ATPase C-termini 
containing the HbYX motif are docked into α-intersubunit pockets in several closed-gate 26S 
structures, the local resolution is >3.5Å28–34 which doesn’t allow identification of specific side chain 
interactions between the HbYX motif and the α-subunits. Therefore, the precise position of the 
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HbYX motif in the α-intersubunit pocket and whether or not it is interacting with the conserved 
residues required for gate opening (e.g. K66, P16) cannot be determined at these resolutions. 
Conflicting evidence between the biochemical and structural studies described above casts doubt 
on the utility of using HbYX derived molecules to activate mammalian proteasomes. Study 2 fills 
this knowledge gap by defining the mechanism of HbYX motif gate activation at the molecular 
level (i.e. displacement of P16 backbone outward from the 20S pore axis resulting from a hydro-
gen bond with the HbYX tyrosine hydroxyl group) and designed a synthetic dipeptide (ZYA) ca-
pable of activating the mammalian 20S gate and increasing protein degradation. ZYA is an effec-
tive gate activator (increasing activity over 50-fold) but has relatively low affinity for the pro-
teasome (~1 mM Kd). Future structure-activity relationship (SAR) models of ZYA-derivatives com-
bined with an iterative process of design and screening can potentially generate new gate-
activating compounds with improved potency and drug-like characteristics.  
III. Future Perspectives 
Impaired proteasome function has been implicated in the development of many neurodegenera-
tive diseases5–9, and increasing proteasome activity has been recognized as a promising new 
approach to delay the onset or ameliorate the symptoms of neurodegenerative and other protein 
misfolding disorders35–37. Taken together, Study 1 and Study 2 identify a mechanism of pro-
teasome impairment by disease-associated oligomers and demonstrate that proteasome gate-
activating molecules can increase protein degradation and overcome neurodegenerative-oligo-
mer impairment. However, our studies were performed in vitro with purified proteasomes, and 
several important questions remain unanswered.  
III.A. In vivo proteasome activation 
While cultured cells, drosophila, and nematodes respond favorably to increased proteasome ac-
tivity (e.g. via ectopic proteasome delivery, proteasome subunit overexpression, genetic open-
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gate mutations)14,17,38–40, these model systems are short-lived compared to humans and cannot 
recapitulate all aspects of human neurogenerative disease. Notably, pathological changes at mo-
lecular and cellular levels in human patients precedes the clinical onset by several years. In fact, 
neuron loss is apparent at the onset of neurological symptoms and that neuronal dysfunction and 
abnormal protein deposited in the brain are already detectable in asymptomatic carriers of a gene 
mutation of familial neurodegenerative disease. We do not know if pharmacologically activating 
the proteasome in an organism with preexisting disease pathology can restore cellular proteosta-
sis and if this is enough to have a positive impact on neural function and human health.   
III.B. Crosstalk between the proteasome and autophagy 
Autophagy is responsible for nonspecific, bulk degradation of cytoplasmic components. Recent 
work has also revealed specific, autophagic degradation of polyubiquitinated proteins and aggre-
gates41,42, and dynamic activity regulation between the UPS and autophagy43–45. Even though 
several biochemical mechanisms underlying crosstalk between them have been suggested45,46, 
less is known about the effect of enhanced proteasome activity on autophagic flux. Studies have 
shown that increased proteasome activity (achieved with hyperactive α3ΔN proteasomes or by 
pharmacological inhibition of USP14) inhibit autophagy flux at the autophagosome–lysosome fu-
sion step14,47. The mechanism of autophagy inhibition appears to involve enhanced proteasomal 
degradation of the autophagosome–lysosome fusion protein, UV radiation resistance-associated 
gene (UVRAG)14,47, p53, and p6214. Consequently, although proteasome activation improved the 
clearance of aggregation-prone proteins and reduced the amount of oligomers14,47, these condi-
tions also increased the formation of inclusion bodies from nonproteasomal substrates (such as 
huntingtin with expanded polyglutamine repeats)47 and the number of GFP-LC3 puncta (a marker 
of autophagosomal structures)14. In contrast, other studies have shown that proteasome activa-
tion through genetic and pharmacological inhibition of USP14 corrected an in vivo model of 
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impaired mitophagy48 and increased autophagic flux49,50, likely through suppression of K63 ubiq-
uitination of Beclin150. 
Taken together, these observations highlight the fact that while a strategy enhancing proteasome 
activity may be beneficial in the treatment of neurodegenerative disease, it may have caveats 
originating from crosstalk mechanisms between the UPS and autophagy. Thus, future efforts are 
needed to address the effect of proteasome activation on autophagy regulatory mechanisms and 
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